Saturday, December 3, 2016

08:00 - 17:00: Workshop (WS01): Young Investigator Research and Communication Training (Sign up Required)
Track: Trial Design/Statistics
Room: Schubert 1 & Schubert 2
Moderator: Lloyd Bracey, UK

The 2016 WCLC Local Organizing Committee is organizing a young investigator communications workshop prior to the 2016 WCLC Conference. The workshop will address how to structure and deliver effective presentations on clinical research, and how to deal with resulting questions effectively. The workshop will comprise two teaching lectures by a lead coach. These will be entertaining and will simultaneously teach and illustrate the principles under discussion. After each lecture participants will break into groups to engage in interactive practical exercises. Every delegate will be expected to participate, including giving a presentation. Applications of interested delegates will include a CV as well as two recommendation letters and will be reviewed by the Local Organizing Committee for final approval and selection. To view the application process, please click here.

09:00 - 18:00: Workshop (WS02): IASLC Supporting the Implementation of Global CT Screening (Ticketed Session: €100,00)

Track: Radiology/Staging/Screening
Room: Strauss 1

Organization Committee:
Chairs: John Field, UK & James L Mulshine, USA
Matthijs Oudkerk, The Netherlands
David Yankelevitz, USA
Annette McWilliams, Australia
Heidi Schmidt, Canada
Hisao Asamura, Japan
Javier Zulueta, Spain
Robert Smith, USA
Nir Peled, Israel

Objectives:

1. This IASLC SSAC Workshop will provide an overview of the recent advances in lung cancer screening.
2. To provide a forum to discuss the pertinent issues around implementation, which will impact on all health services as they move towards implementation.
3. What can be achieved in the next three years and recommendation for the IASLC Exec as to how they can support leadership in this area of lung cancer.
4. The consensus from this workshop will be published.

Program:

09.00 - Welcome and Aims of Workshop - John K. Field, UK

Session 1: 09.10 - 09.50
Integrating Smoking Cessation into Future Lung Cancer CT Screening Programs - Utilizing the ‘Teachable Moment’

**Chairs:** Avi Spira, USA & Robert Smith, USA

- **09.10** - Personalize Tobacco Cessation in the CT Screening Setting
  Jamie Ostroff, USA
- **09.25** - Opportunities to Enhance the Cost Effectiveness of CT Screening through the Integration of Tobacco Cessation
  William Evans, Canada
- **09.40** - Discussion

**Session 2: 09.50 - 11.00**

Radiological Imaging and Work-Up

**Chairs:** Heidi Schmidt, Canada, Arnie Devaraj, UK, Pierre Massion, USA & Nir Peled, Israel

- **09.50** - CT Scan Detected Nodule Management Protocol
  Matthijs Oudkerk, The Netherlands
- **10.05** - Innovative Approaches to Quantitative Imaging Quality Control for Lung Cancer Screening
  Ricardo Avila, USA
- **10.20** - Opportunities to Advance Lung Cancer Screening Approaches Using Data Registries
  David Yankelevitz, USA
- **10.35** - Progress in Advancing Lung Cancer Screening Internationally
  John K Field, UK
- **10.50** - Discussion
- **11.00** - Coffee Break

**Session 3: 11.30 - 12.30**

Integration of Molecular Biomarkers and Utilization of CT for CHD & COPD

**Chairs:** Gabriella Sozzi, Italy, Javier Zulueta, Spain & Claudia Henschke, USA

- **11.30** - The Power of Micro Simulation Modelling in Lung Cancer Screening
  Kevin Ten Haaf, The Netherlands
- **11.45** - ImaLife
  Rozemarijn Vliegenthart, The Netherlands
- **12.00** - Lung CT Screening: Complementary Benefits - CHD & COPD
  Claudia Henschke, USA
- **12.15** - Discussion
- **12.30** - Lunch

**Session 4: 13.30 - 15.50**

The Current Global Implementation of CT Lung Cancer Screening Programs Outside the USA (Please note 10 minutes per presentation)

**Chairs:** Matthijs Oudkerk, The Netherlands, Kwun Fong, Australia, David Baldwin, UK, Shun-ichi Watanabe, Japan, Robert Smith, USA

- **13.30** - The Shanghai Screening Trial
  Liu Shi-Yuan, China
- **13.50** - Update on Low-dose CT Lung Cancer Screening Implementation in USA
  James Mulshine, USA
• 14.00 - The Current Implementation Plan in Canada
  Stephen Lam, Canada
• 14.10 - Surgical Status of Screen Detected Lung Cancer - Future Prospective?
  Shun-ichi Watanabe, Japan
• 14.20 - Lung Cancer Screening in Australia
  Kwun Fong, Australia
• 14.30 - Developing Lung Cancer Screening Plans in South America
  Ricardo Terra, Brazil
• 14.40 - Annual or Biennial Lung Cancer Screening - What Is the Evidence?
  David Yankelevitz, USA
• 14.50 - Netherlands & Europe Awaiting the NELSON Publication Prior to Implementation
  Harry De Koning, The Netherlands
• 15.00 - US National Lung Cancer Round Table
  Robert Smith, USA
• 15.10 - Discussion
• 15.50 - Tea Break

Session 5: 16.20 - 17.30 (Round Table Discussion)
What can be achieved in the next three years and recommendation for the IASLC Exec as to how they can support leadership in this area of lung cancer.

Chairs: John K Field, UK & Jim Mulshine, USA

Each Question will be addressed for 3 minutes by the Lead Discussant and then opened up for general discussion.

Questions to be addressed:

1. Identification of the hard to reach community for lung cancer screening - how?
   Discussant: David Baldwin, UK
2. Use of quantitative imaging in the screening setting - do we need accreditation?
   Discussant: Matthijs Oudkerk, The Netherlands
3. CT screen detected registries - what are the possibilities for international co-operation?
   Discussant: David Yankelevitz, USA
4. How do we develop international recommendation for the work-up of CT screen detected nodules?
   Discussant: Ricardo Avila, USA
5. How can IASC Exec support leadership in lung cancer CT screening?
   Discussants: John K Field, UK & Jim Mulshine, USA

18.00: Networking Dinner

The CT Screening Workshop Registration cost includes: Buffet, Lunch & Dinner
CPD Accredited Workshop (6 points)

14:00 - 16:00: Tobacco Control in Central Europe: Status - Goals - Challenges
Room: Strauss 2
Sunday, December 4, 2016

08:00 - 11:45: (JCES01) Joint IASLC - Chinese Society for Clinical Oncology - Chinese Alliance Against Lung Cancer Session (Sign up Required)
Room: Stolz 1
Chairs: Fred R. Hirsch, USA & Yi Long Wu, China, ChunXue Bai, China

- 08:00 - Breakfast and Informal Networking
- 08:20 - Welcome and Introduction
  Fred R. Hirsch, USA & Yi Long Wu, China, ChunXue Bai, China

Discovering the East: Precision Medicine in China

- 08:30 - JCES01.03: Perspectives on Precision Medicine for Early Stage NSCLC
  Jie Hu, China
- 08:50 - JCES01.04: Liquid Biopsy in Monitoring Dynamic Changes of Driver Genes in Advanced NSCLC
  Qing Zhou, China
- 09:10 - JCES01.05: New Clinical Trials on Gene Alteration in China
  Shun Lu, China

Precision Medicine - Perspectives from the West

- 09:30 - JCES01.06: European Perspective Phase I Strategy
  Christian Diego Rolfo, Belgium
- 09:50 - JCES01.07: North American Perspective
  Paul Bunn, Jr., USA

Break - 10:10 - 10:30

Abstract Presentations from China Related to Precision Medicine

- 10:30 - JCES01.09: A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR-TKI Resistance
  Wenxian Wang, China
- 10:40 - JCES01.10: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer
  Zhengbo Song, China
- 10:50 - JCES01.11: Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma
  Yue Zhao, China
- 11:00 - Discussant Oral Abstracts
  James Chih-Hsin Yang, Taiwan
- 11:15 - Discussant Posters
  Xu-Chao Zhang, China
  o JCES01.14: Mutational Profiling of Non-Small-Cell Lung Cancer Patients Resistant to First-Generation EGFR Tyrosine Kinase Inhibitors Using next Generation Sequencing
    - Ying Jin, China
  o JCES01.15: Analysis of Genomic Alterations and Heterogeneity in Pulmonary Adenoid Cystic Carcinoma by Next-Generation Sequencing
    - Min Li, China
• JCES01.16: A MET Inhibitor in the Treatment of Metastatic Non Small Cell Lung Cancer with MET Amplification - Junling Li, China
• JCES01.17: A Phase I Dose Expansion Study of Epitinib to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm+) NSCLC Patients with Brain Metastasis - Qing Zhou, China
• JCES01.18: Dual Positive PD-L1 and CD8+ TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity - Si-Yang Liu, China
• JCES01.19: Clinicopathologic Characteristics, Genetic Variability and Therapeutic Options of RET Rearrangement Patients in Lung Adenocarcinoma - Zhengbo Song, China
• JCES01.20: Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy - Zhengbo Song, China
• JCES01.21: Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection - Zhengbo Song, China
• JCES01.22: Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Patients with Non-Small Cell Lung Carcinoma - Ting Xu, China
• JCES01.23: EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases - Zhe Liu, China
• JCES01.24: Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TK - Jiefei Han, China

11:30 - Closing Remarks

08:00 - 11:45: Young Investigator Session (YI01a): Clinical Trials & Scientific Mentoring
Clinical Trials: Design, Publication & Interpretation
Room: Hall C8
Chairs: Luigi De Petris, Sweden & TBD

• 08:00 - How to Implement an Idea/Hypothesis into a Clinical Trial
Carlos Silva, Argentina
• 08:20 - Basic Statistical Considerations
Lothar Pilz, Germany
• 08:40 - How to Effectively Publish your Results: Suggestions from the JTO Editor
Alex Adjei, USA
• 09:00 - Critical Eye on Practice Changing Literature
Jin Soo Lee, South Korea

09:30 - Coffee Break
09:45 - Young Investigator Session (YI01b): Scientific mentoring
Chairs: Amanda Tufman, Germany & Alex Adjei, USA

• 09:45 - Important Factors for a Professional Career
Martin Edelman, USA
• 10:05 - Expectations from a Young Investigator
Matthias Scheffler, Germany
• 10:20 - Scientific Mentoring: The Reality
Mirjana Rajer, Slovenia
• 10:35 - Scientific Mentoring in Austria: My Personal Experience
Anna Buder, Austria
• 10:50 - Meeting with Scientists
Alex Adjei, USA, Martin Edelman, USA, James Jett, USA, Jin Soo Lee, South Korea, Carlos Silva, Argentina & Zhijie Wang, China

08:00 - 11:45: Workshop (WS03): IASLC Meets ESTI: Imaging in Lung Cancer Staging and Diagnosis
Track: Radiology/Staging/Screening
Room: Strauss 2
Chairs: Helmut Prosch, Austria & Ramon Rami-Porta, Spain

- **T Stage**
  Helmut Prosch, Austria

- **N Stage**
  Cornelia Schäfer-Prokop, The Netherlands

- **M Stage**
  Nicola Sverzellati, Italy

- **Ultrasound- and CT-Guided Biopsies for the Diagnosis of Lung Cancer**
  Gerhard Mostbeck, Austria

08:00 - 11:00: Mesothelioma Workshop (WS04) (Ticketed Session €25,00)
Room: Stolz 2
Chair: Michele Carbone, USA

- 08:00 - Debate - Extrapeural Pneumonectomies Should NOT be Performed for Pleural Mesothelioma
  David Jablons, USA, Raja Flores, USA & Isabelle Schmitt-Opitz, Switzerland

- 08:50 - Q&A

- 09:00 - Debate - Immunotherapy Does NOT Work in Mesothelioma
  Hedy Kindler, USA, Luciano Mutti, UK, Paul Bass, The Netherlands & Daniel Sterman, USA

- 09:50 - Q&A

- 10:00 - Debate - Induction Chemotherapy is Better than Postoperative Adjuvant Therapy for Early Stage Pleural Mesothelioma
  Anne Tsao, USA, Walter Weder, Switzerland, Marc de Perrot, Canada, Wickii Vigneswaran, USA

- 10:50 - Q&A

08:00 - 12:00: (WS05): International Society of Nurses in Cancer Care (ISNCC) & BMS Foundation Collaborative Workshop (Sign up Required)
Track: Nurses
Room: Schubert 4-5

- How to Develop a Comprehensive System of Care for Lung Cancer Patients
  Bristol-Myers Squibb

08:00 - 13:00: (WS06) Management of Lung Cancer Patients Through Innovative Laboratory Testing Across the Clinical Continuum Workshop (Sign up Required)
Sponsored by Roche.
Chair: Felix Herth, Germany
Room: Strauss 1

- 08:00 - Introduction
  Felix Herth, Germany
08:15 - Serum-based Protein Tumor Markers
Rafael Molina, Spain

09:00 - Lung Panel IHC, PD-L1, ALK, ROS1, EGFR
Fernando Lopez-Rios, Spain

09:55 - EGFR Plasma
David Gonzalez de Castro, UK

10:40 - Sequencing Data
Max Diehn, USA

11:25 - Summary
Felix Herth, Germany

11:40 - Panel Discussion
Keith Miller, USA, Rafael Molina, Spain, Fernando Lopez-Rios, Spain, David Gonzalez de Castro, UK, Max Diehn, USA & Felix Herth, Germany

12:15 - Coffee and Pastries at Opening and Box Lunches Offered at End of Session

10:30 - 11:45: Press Conference (PR01)
Room: Schubert 1
Chairs: Robert Pirker, Medical University of Vienna, Austria & David Carbone, The Ohio State Wexner Medical Center, USA

- PR01.01: Welcome - Fred Hirsch, University of Colorado Cancer Center, USA & Robert Pirker, Medical University of Vienna, Austria
- PR01.02: Shared Decision Making (SDM) and Patient Decision Aids (PDAs) in Lung Cancer: Survey of Patients, Significant Others or Caregivers - Laurie Gaspar, University of Colorado, USA
- PR01.03: The ALCF Centers of Excellence Model Delivers a Standard of Care to the Community Similar to Academic and Research Centers - Raymond Osarogiagbon, Baptist Cancer Center, USA
- PR01.04: Mesothelioma Workshop
- PR01.05: E-health and Future Technologies in Evidence Based Nursing Care - Roma Maguire, University of Surrey, UK
- PR01.06: Honored Guest

12:00 - 13:30: Industry Supported Symposium: ISS Current and Emerging Treatments for Patients with ALK+ NSCLC - ARIAD Pharmaceuticals Inc.
Room: Strauss 3
Chairs: Christoph Zielinski, Austria & D. Ross Camidge, USA

- 12:00 - Welcome & Introduction
  Christoph Zielinski, Austria & D. Ross Camidge, USA
- 12:05 - ALK inhibitors: Current Treatments and Sequencing
  Christoph Zielinski, Austria
- 12:30 - The Future of ALK Inhibitors: How the Treatment Paradigm May Change
  D. Ross Camidge, USA
- 12:55 - Will Mutation Testing be Standard in the Resistant Setting?
  Pasi A. Jänne, USA
- 13:20 - Summary and Conclusions
  Christoph Zielinski, Austria & D. Ross Camidge, USA
13:45 - 15:15: Industry Supported Symposium: ISS ALK and ROS1 in NSCLC: Optimising the Continuum of Care- Pfizer Oncology
Room: Lehar 3-4
Chair: Benjamin Solomon, Australia

- 13:45 - Welcome & Introduction
  Benjamin Solomon, Australia
- 13:50 - The Importance of Molecular Testing in NSCLC
  Benjamin Solomon, Australia
- 14:00 - ALK+ NSCLC: How can we Maximise Clinical Outcome Today?
  Nicolas Girard, France
- 14:20 - Clinical Consequences of Resistance to ALK Inhibitors
  Christine Lovly, USA
- 14:40 - Panel Discussion
  All Faculty
- 14:50 - ROS1+ NSCLC: Clinical Data and Experience
  Benjamin Solomon, Australia
- 15:05 - Panel Discussion
  All Faculty
- 15:10 - Meeting Close
  Benjamin Solomon, Australia

13:30 - 18:30: (WS07) International Thoracic Oncology Nursing Forum (ITONF) and Mesothelioma Satellite Workshop: Innovating Lung Cancer and Mesothelioma Care (Ticketed Session: €25,00)
Track: Nurses
Room: Schubert 2
Chair: John McPhelim, UK

Globalization of Nursing in Lung Cancer and Mesothelioma Care

- 13.30 - Opening - Welcome
  Maria Guerin, UK
- 13.35 - Leveraging Technology and Social Media in Nursing
  Anne Ireland, USA
- 14:00 - E-health and Future Technologies in Evidence Based Nursing Care
  Roma Maguire, UK
- 14:20 - Nursing Management in Japan
  Sarah Nagamatsu, Japan
- 14:35 - Q&A
  Panel Discussion

Immunotherapy - The New Kid on the Block

- 14:40 - Immunotherapy Challenges in Lung Cancer & Mesothelioma
  Sanjay Popat, UK
- 15:05 - Nursing Opportunities & Challenges for Immunotherapy
  Beth Eaby-Sandy, USA
- 15:20 - Nurse Led Follow up Clinics - Effective in Immunotherapy?
  Mary Duffy, Australia
- 15:35 - Q&A
Clinical Trials - Supporting Trials and Our Patients
Chair: Mary Duffy, Australia

- 16:00 - Clinical Trial Participation - The Nurses Role
  Massey Nematollahi, Canada
- 16:15 - Lung Cancer Nurse Attitudes to Clinical Research in the UK
  John McPhelim, UK
- 16:30 - Considerations for Surgical Clinical Trials
  Melissa Culligan, USA
- 16:45 - Q&A
  Panel Discussion

Changing Face of Lung Cancer
Chair: Mary Duffy, Australia

- 16:50 - Frailty Assessment Prior to Treatment Initiation
  Patsy Yates, Australia
- 17:10 - A Glimpse into Lung Cancer Nursing in Denmark
  Marianne Cumberland, Denmark
- 17:25 - New Lung Cancer Patient Resource
  Silvia Novello, Italy
- 17:35 - Q&A

Smoking Cessation in Lung Cancer and Mesothelioma Patients
Chair: Mary Duffy, Australia

- 17:40 - Vapping - A Good Smoking Cessation Tool?
  Sanjay Agrawal, UK
- 17:55 - Smoking Cessation - It’s the Nurses Role?
  Caitlin Broderick, Australia
- 18:10 - Q&A
- 18:25 - Close
  Melissa Culligan, USA

15:30 - 17:00: Industry Supported Symposium: ISS Non-Small Cell Lung Cancer: The Programmed Death-Ligand 1 (PD-L1) as a Target for Monotherapy and in Combination - Merck-Pfizer Alliance
Room: Hall C2
Chair: Sanjay Popat, UK

- 15:30 - Welcome and Overview
  Sanjay Popat, UK
  Rosalyn Juergens, Canada
- 16:00 - Anti-PD-L1 Combined with Other Agents in NSCLC: Combinations with non-Immunooncology Agents
  Jhannelle Gray, USA
- 16:15 - Anti-PD-L1 Combined with Other Agents in NSCLC: Immuno-Oncology Combinations
  Sacha Rothschild, Switzerland
16:30 - Anti-PD-L1 Agents: Opportunities for Differentiation  
Hossein Borghaei, USA

16:45 - Summary, Questions and Close  
Sanjay Popat, UK

17:15 - 18:45: Industry Supported Symposium: ISS Treatment Selection Strategies in Advanced NSCLC - A Symphony of Views - Eli Lilly and Company  
Room: Hall C1  
Chairs: Giorgio Scagliotti, Italy & Tony Mok, Hong Kong

- 17:15 - Welcome & Introduction  
Giorgio Scagliotti, Italy & Tony Mok, Hong Kong

- 17:20 - Orchestral Manoeuvres of the Immuno Checkpoints: Targeted or Untargeted Agents?  
Joachim Aerts, The Netherlands

- 17:45 - Variation on a Theme: Angiogenesis Inhibition Across Treatment Lines  
Maurice Pérol, France

- 18:05 - Keys to Biomarker Driven Choices in 2nd Line  
Luis Paz-Ares, Spain

- 18:25 - Is the Score Yet Written?  
Giorgio Scagliotti, Italy

- 18:30 - Discussion: the Unfinished Symphony  
Tony Mok, Hong Kong

19:00 - 20:45: Opening Plenary Session (PL01)  
Room: Hall D (Plenary Hall)

- Welcome Address  
Robert Pirker, Austria, Conference President

- Welcome Address  
David Carbone, USA, IASLC President

- Distinguished Award Winner Presentations  
Fred Hirsch, USA, IASLC CEO

- Vienna Boys Choir

- Keynote Lecture: Is Smoking a Sole Factor in Lung Cancer Development?  
Harald zur Hausen, Nobel Laureate, Germany

- Vienna Boys Choir

20:45 - 21:45: Welcome Reception  
Room: Hall B (Exhibit Hall)
Monday, December 5, 2016

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH01)
Tracks: Epidemiology/Tobacco Control and Cessation/Prevention
      Biology/Pathology
Room: Hall C1
Chairs: Martin Filipits, Austria & Tetsuya Mitsudomi, Japan

- **Prevention**
  Carolyn Dresler, USA
- **Biology**
  Roman Thomas, Germany
- **Pathology**
  Keith Kerr, UK

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH02)
Tracks: SCLC/Neuroendocrine Tumors
      Mesothenlioma/Thymic Malignancies/Eosophageal Cancer/Other Thoracic Malignancies
Room: Hall C7
Chairs: Raffit Hassan, USA & Georg Pall, Germany

- **SCLC**
  Joan Schiller, USA
- **Malignant Pleural Mesothelioma**
  Anna Nowak, Australia
- **Thymic Malignancies & Eosophageal Cancer**
  Peter Hohenberger, Germany

07:30 - 08:30: Meet the Expert (MTE01) (Ticketed Session: €35,00)
Track: Epidemiology/Tobacco Control and Cessation/Prevention
Room: Schubert 1

- **Strategies to Improve Tobacco Control in Central European Countries**
  Manfred Neuberger, Austria & Martina Pötschke-Langer, Germany

07:30 - 08:30: Meet the Expert (MTE02) (Ticketed Session: €35,00)
Track: Biology/Pathology
Room: Schubert 2

- **Advances in Pathology**
  Lukas Bubendorf, Switzerland

07:30 - 08:30: Meet the Expert (MTE03) (Ticketed Session: €35,00)
Track: Biology/Pathology
Room: Schubert 4

- **Basics of Molecular Biology for the Clinician**
  Antonio Marchetti, Italy

07:30 - 08:30: Meet the Expert (MTE04) (Ticketed Session: €35,00)
Track: Radiology/Staging/Screening
Room: Schubert 5
• **Screening for Lung Cancer**  
  Christine Berg, USA & Nir Peled, Israel

07:30 - 08:30: **Meet the Expert (MTE05) (Ticketed Session: €35,00)**  
Track: Surgery | Radiotherapy | Locally Advanced NSCLC  
Room: Schubert 6  
  • **Where is the Place of Surgery for N2 Disease?**  
    Corinne Faivre-Finn, UK & Paul Van Schil, Belgium

07:30 - 08:30: **Meet the Expert (MTE06) (Ticketed Session: €35,00)**  
Track: Radiotherapy  
Room: Strauss 3  
  • **Radiotherapy Techniques in Lung Cancer**  
    Ritsuko Komaki, USA & Martin Stuschke, Germany

07:30 - 08:30: **Meet the Expert (MTE07) (Ticketed Session: €35,00)**  
Track: Chemotherapy/Targeted Therapy/Immunotherapy | Advanced NSCLC  
Room: Lehár 1-2  
  • **Treatment of Elderly Patients with Lung Cancer**  
    Cesare Gridelli, Italy & Corey Langer, USA

07:30 - 08:30: **Meet the Expert (MTE08) (Ticketed Session: €35,00)**  
Track: Chemotherapy/Targeted Therapy/Immunotherapy | Early Stage NSCLC | Locally Advanced NSCLC  
Room: Lehár 3-4  
  • **Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives**  
    Charles Butts, Canada & Frank Griesinger, Germany

07:30 - 08:30: **Meet the Expert (MTE09) (Ticketed Session: €35,00)**  
Track: Chemotherapy/Targeted Therapy/Immunotherapy  
Room: Stolz 1  
  • **Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC**  
    Jie Wang, China & Sabine Zöchbauer-Müller, Austria

07:30 - 08:30: **Special Session (WS08): CAP/IASLC/AMP Guidelines for Molecular Testing in Lung Cancer**  
Room: Strauss 1  
Speakers and Chairs: Ming-Sound Tsao, Canada & Yasushi Yatabe, Japan

07:30 - 08:30: **Industry Supported Symposia: ISS Orchestrating Progress for Patients with Squamous Cell Lung Cancer - Eli Lilly and Company**  
Room: Strauss 2  
Chair: Silvia Novello, Italy

• 07:30 - **Squamous Cell Lung Cancer - A Different Tune**  
    Johan Vansteenkiste, Belgium
• 07:45 - **Hitting the Right Notes for Clinical Efficacy**  
    John Gosney, UK
• 08:00 - **Fine Tuning Patient Outcomes by Selecting the Right Treatment, for the Right Patient, at the Right Time**  
    David Gandara, USA
**08:15 - Harmonising Patients Understanding of their Diagnosis and Treatment Plan: Introducing the Squamous Cell Lung Cancer Patient Booklet**
Silvia Novello, Italy

**08:20 - Discussion**

07:30 - 08:30: Industry Supported Symposium: ISS The Changing Treatment Paradigm After Progression in Advanced EGFR-Mutated NSCLC - PeerVoice
Room: Stolz 2
Chair: James Chih-Hsin Yang, Taiwan (Moderator)

- **07:30 - Introduction: The Path Forward in Advanced EGFR-Mutated NSCLC**
  James Chih-Hsin Yang, Taiwan (Moderator)
- **07:35 - Emerging Algorithm for Advanced EGFR-Mutated NSCLC After Progression**
  Anders Mellemgaard, Denmark
- **07:45 - Best Practices for Managing Advanced EGFR-Mutated NSCLC After Progression**
  Howard West, USA
- **07:55 - Panel Discussion: Overcoming Obstacles Managing Advanced EGFR-Mutated NSCLC After Progression**
  All Faculty
- **08:15 - Conclusions & Questions**
  James Chih-Hsin Yang, Taiwan (Moderator)

08:45 - 09:00: Distinguished Lecture (PL02a)
Room: Hall D (Plenary Hall)
Chairs: Robert Pirker, Austria, David Carbone, USA & Fred Hirsch, USA

- **Welcome Address**
  Heinz Fischer, Former Federal President of the Republic of Austria (2004-2016)

09:00 - 10:20: Plenary Session (PL02b): Tobacco Control
Chairs: Carolyn Dresler, USA & Peter Goldstraw, UK

- **09:00 - PL02b.01: Implementing Tobacco Control Measures in Uruguay**
  Tabaré Vázquez, Uruguay
- **09:25 - PL02b.02: Framework Convention on Tobacco Control: Its impact on Global Health**
  Vera da Costa e Silva, Switzerland
- **09:45 - PL02b.03: Free Trade & Investment Agreement Threatens Public Health**
  Zarithah Zain, Malaysia
- **10:00 - PL02b.04: Tobacco Control**
  Luke Clancy, Ireland

10:25 - 10:55: Exhibit Showcase Session: Roche Tissue Diagnostics
Room: Hall B (Exhibit Showcase Theater)

When H&E is not enough: Immunostaining & biomarker trends and EQA surveillance in lung cancer diagnostics.

Modern approaches to staining lung biopsy samples and current EQA data on ALK and PD-L1.

10:25 - 11:00: Poster Session
Room: Hall B (Poster Area)
10:30 - 11:45: Press Conference (PR02): Active Prevention
Room: Schubert 1
Chairs: Jacek Jassem, Medical University of Gdansk, Poland

- **PR02.01: Implementing Tobacco Control Measures in Uruguay** - Tabaré Vázquez, President of Uruguay, Uruguay
- **PR02.02: Framework Convention on Tobacco Control: Its impact on Global Health** - Vera da Costa e Silva, WHO Framework Convention on Tobacco Control, Switzerland
- **PR02.03: Free Trade & Investment Agreement Threatens Public Health** - Zarihah Zain, Lincoln University College Malaysia, Malaysia
- **PR02.04: Tobacco Control** - Luke Clancy, TobaccoFree Research Institute Ireland, Ireland
- **PR02.05: Tobacco-free Investments and Portfolios** - Bronwyn King, Tobacco Free Portfolios, Australia

11:00 - 12:30: Educational Session (ED01): Biology of Lung Cancer
Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C1

Chairs: Rafael Rosell, Spain & Martin Filipits, Austria

- 11:00 - 11:25: Understanding Biology: The Road to Cure?
  David Carbone, USA
- 11:25 - 11:50: Tobacco Carcinogens and Lung Cancer Susceptibility
  Stephen Hecht, USA
- 11:50 - 12:15: Insights from TCGA
  Ramaswamy Govindan, USA

11:00 - 12:30: Educational Session (ED02): Palliative Care in Lung Cancer: A Global Challenge
Track: Palliative Care/Ethics
Room: Strauss 3
Chairs: Jeffrey Crawford, USA & Jean Klastersky, Belgium

- 11:00 - Palliative Care and its Importance for Patients with Lung Cancer
  Herbert Watzke, Austria
- 11:20 - Palliative Care in South America
  Luis Alberto Mas Lopez, Peru
- 11:35 - Palliative Care in India
  Gouri Shankar Bhattacharyya, India
- 11:50 - Palliative Care in South-East Asia
  Richard B. L. Lim, Malaysia
- 12:05 - Palliative Care in Iran
  Reza Malayeri, Iran

11:00 - 12:30: Science Session (SC01): Staging Before and After Induction Therapy for N2 Disease
Track: Radiology/Staging/Screening | Locally Advanced NSCLC
Room: Lehar 3-4
Chairs: Elie Fadel, France & Gerhard Mostbeck, Austria

- 11:00 - The Importance of Mediastinal Down-Staging During Induction Therapy of N2 Disease
  Paul de Leyn, Belgium
• 11:20 - PET-CT for Response Assessment During Induction Therapy of N2 NSCLC
  Christoph Pöttgen, Germany
• 11:35 - EBUS/EUS for Staging During Induction Therapy of N2 NSCLC
  Franz Stanzel, Germany
• 11:50 - The Role of Mediastinoscopy in Induction Therapy of N2 NSCLC
  Sergi Call, Spain
• 12:05 - Video-Thoracoscropy for Staging of N2 NSCLC During Induction Therapy
  Thomas D'Amico, USA
• 12:20 - Q&A

11:00 - 12:30: Science Session (SC02): Multifocal Lung Cancer
Track: Pulmonology | Radiology/Staging/Screening
Room: Strauss 1
Chairs: Giulia Veronesi, Italy & Saulus Cicenas, Lithuania

• 11:00 - Multiple Primary Lung Cancers Versus Lung Metastases: Pathological Differential Diagnosis
  Erik Thunnissen, The Netherlands
• 11:20 - Surgical Choices for Patients with Multifocal Lung Cancer
  Scott Swanson, USA
• 11:50 - Surgery for Ground Glass Opacity: Sublobar Resection?
  Shun-Ichi Watanabe, Japan
• 12:10 - Interactive Presentation of Clinical Cases with Multifocal Lung Cancer
  Alper Toker, Turkey

11:00 - 12:30: Science Session (SC03): Advances in Radiation Oncology
Track: Radiotherapy
Room: Strauss 2
Chairs: Hak Choy, USA & Richard Pötter, Austria

• 11:00 - Advances in Stereotactic Body Radiotherapy
  Matthias Guckenberger, Switzerland
• 11:20 - Proton Therapy of Lung Cancer
  Jeffrey Bradley, USA
• 11:40 - Carbon-Ion Therapy of Lung Cancer
  Yuko Nakayama, Japan
• 11:55 - Molecular Predictive Biomarkers for Radiotherapy Outcome in Lung Cancer
  Walter Curran, USA
• 12:10 - Radiotherapy Combined with Targeted Therapies or Immunotherapy
  Jinming Yu, China

11:00 - 12:30: Science Session (SC04): EGFR Tyrosine Kinase Inhibitors: A Model for Successful Drug Development
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C7
Chairs: Sumitra Thongprasert, Thailand & Oliver Gautschi, Switzerland

• 11:00 - First- and Second Generation EGFR Tyrosine Kinase Inhibitors
  James Chih-Hsin Yang, Taiwan
• 11:20 - Management of Resistance to EGFR Tyrosine Kinase Inhibitors
  Tetsuya Mitsudomi, Japan
• 11:40 - Sequencing of EGFR Tyrosine Kinase Inhibitors  
  Keunchil Park, South Korea  
 12:00 - Liquid Biopsies for Dynamic Monitoring of EGFR Mutations in Lung Cancer  
  Martin Schuler, Germany  
 12:20 - Q&A

11:00 - 12:30: Science Session (SC05): Novel Drugs in Thoracic Cancers  
Track: Chemotherapy/Targeted Therapy/Immunotherapy  
Room: Hall C2  
Chairs: Roy Herbst, USA & Nagahiro Saijo, Japan

• 11:00 - Immunotherapy in Malignant Pleural Mesothelioma  
  Raffit Hassan, USA  
• 11:20 - Novel Cytotoxic Drugs in Lung Cancer  
  Jean-Charles Soria, France  
• 11:40 - Novel Tyrosine Kinase Inhibitors in Lung Cancer  
  Caicun Zhou, China  
• 12:00 - Lung Cancer Vaccines: An Update  
  Elisabeth Quoix, France  
• 12:20 - Q&A

11:00 - 12:20: Interactive Session (IA01): Multidisciplinary Diagnosis of Lung Cancer in the Era of Molecular Medicine  
Track: Biology/Pathology | Radiology/Staging/Screening  
Room: Stolz 1  
Chairs: Kwun Fong, Australia & Ales Ryska, Czech Republic

• 11:00 - The Role Pathology for Diagnosis and Treatment of Lung Cancer  
  Helmut Popper, Austria  
• 11:20 - What Endoscopic Techniques can Contribute for Specimen Acquisition  
  Arschang Valipour, Austria  
• 11:40 - What Every Lung Pathologist Needs to Know About Thoracic Surgery  
  Hans Hoffmann, Germany  
• 12:00 - Does Cytological Material Fit All - Lessons from EBUS/Bronchoscopy  
  Wlodzimierz Olszewski, Poland

11:00 - 12:30: Interactive Session (IA02): Staging* (Ticketed session: €35,00)  
Group I (Space is limited to 20 participants)  
Track: Radiology/Staging/Screening  
Room: Schubert 3  
Coordinators: Karin Dieckmann, Austria & Helmut Prosch, Austria  
Trainers: Libor Havel, Czech Republic, Anna Kerpel-Fronius, Hungary & Elisabeth Stiefsohn, Austria  
*Please note that this session is a duplicate of the session on Tuesday

11:00 - 12:30: Nurses Session (NU01): Prevention  
Track: Nurses | Epidemiology/Tobacco Control and Cessation/Prevention  
Room: Schubert 5  
Chairs: Liz Darlington, UK & Iveta Nohavova, Czech Republic

• 11:00 - China at the Crossroads: Findings from the ITC China Project on the Current State of Tobacco Control in China
Geoffrey Fong, Canada

- 11:20 - Global View of Smoking Cessation
  Stella Bialous, USA

- 11:40 - The Role of Oncology Nurses & Smoking Cessation
  Iveta Nohavova, Czech Republic

- 12:00 - Stigma in Lung Cancer
  Janine Cataldo, USA

- 12:15 - Indigenous Population with Lung Cancer
  Gail Garvey, Australia

11:00 - 12:30: Patient Advocacy Session (PA01): Lung Cancer Diagnosis and Care: Identifying and Improving Community Standards
Track: Patient Support and Advocacy Groups
Room: Schubert 6
Chairs: Bonnie Addario, USA & Blaž Bajec, Slovenia

- 11:00 - The Importance of Patient Access to Molecular Testing and Novel Therapies
  Janet Freeman-Daily, USA

- 11:20 - The Route to Diagnosis: Impacting Survival by Changing the System
  Thomas Newsom-Davis, UK

- 11:40 - Establishing a Paradigm for High Quality Lung Cancer Treatment
  David LeDuc, USA

- 12:00 - Nurse-Led Lung Cancer Support Service
  Claire Mulvihill, Australia

- 12:15 - Lung Cancer Management in Turkey
  Seda Kansu, Turkey

11:00 - 12:30: Concurrent Abstract Sessions

11:00 - 12:30: Oral Session (OA01): Risk Assessment and Follow up in Surgical Patients
Track: Surgery
Room: Schubert 2
Chairs: Eric Lim, UK & Wen-Zhao Zhong, China

- 11:00 - OA01.01: Institutional-Based Differences in the Quality and Outcomes of US Lung Cancer Resections
  Raymond Osarogiagbon, USA

- 11:10 - OA01.02: A Lung Cancer Surgical Mortality Risk-Prediction Algorithm to Inform Lung Cancer Screening Shared Decision-Making
  Joshua Roth, USA

- 11:20 - OA01.03: Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Stage I NSCLC Patients: A Competing Risk Analysis
  Takashi Eguchi, USA

- 11:30 - OA01.04: Discussant:
  Alessandro Brunelli, UK

- 11:45 - OA01.05: The Impact of Lung Age on Postoperative Complications in Patients with Lung Cancer Combined with Pulmonary Fibrosis and Emphysema - Masahito Naito, Japan

- 11:55 - OA01.06: Early Post-Operative Ambulation after Thoracic Surgery - The WAVE Experience
  Sandeep Khandhar, USA
• 12:05 - OA01.07: Alternative Follow-Up Methods Based on Recurrence Patterns after Surgery for Non-Small Cell Lung Cancer - Katsuya Watanabe, Japan
• 12:15 - OA01.08: Discussant: Thomas Klikovits, Austria

11:00 - 12:30: Oral Session (OA02): Novel Targets and Biomarkers in Malignant Pleural Mesothelioma
Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
Room: Stolz 2
Chairs: Luis Raez, USA & Marko Jakopovic, Croatia

• 11:00 - OA02.01: The microRNA-15/16 Family Regulates Tumour Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma
  Karin Schelch, Australia
• 11:10 - OA02.02: Gremlin-1 is a Key Regulator of the Invasive Phenotype in Mesothelioma
  Katri Koli, Finland
• 11:20 - OA02.03: Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study
  Yawen Dong, Austria
• 11:30 - OA02.04: Discussant:
  Michaela Kirschner, Switzerland
• 11:45 - OA02.05: Expression of miR-223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumour Microenvironment
  Kadir Sarun, Australia
• 11:55 - OA02.06: Converting Tumor-Mediated PD-L1 Inhibition into CAR T-Cell Costimulation to Potentiate Thoracic Cancers Immunotherapy
  Prasad Adusumilli, USA
• 12:05 - OA02.07: Characterization of the Tumor Microenvironment and Investigation of Immune Checkpoint Expression in Malignant Pleural Mesothelioma
  Elly Marcq, Belgium
• 12:15 - OA02.08: Discussant:
  Michael Grusch, Austria

11:00 - 12:30: Oral Session (OA03): Immunotherapy Checkpoint Inhibitors in Advanced NSCLC
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C8
Chairs: Lucio Crinò, Italy & Tanja Čufer, Slovenia

• 11:00 - OA03.01: First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
  Scott Gettinger, USA
• 11:10 - OA03.02: Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1-Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study
  Marina Garassino, Italy
• 11:20 - OA03.03: JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC
  Claire Verschraegen, USA
• 11:30 - OA03.04: Discussant:
  Edward Garon, USA
• 11:45 - OA03.05: Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
  Solange Peters, Switzerland
• 11:55 - OA03.06: Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC)  
  Rathi Pillai, USA

• 12:05 - OA03.07: KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab  
  Roy Herbst, USA

• 12:15 - OA03.08: Discusssant:  
  Paul Mitchell, Australia

11:00 - 12:30: Oral Session (OA04): Epidemiology and Prevention of Lung Cancer  
Track: Epidemiology/Tobacco Control and Cessation/Prevention  
Room: Schubert 4  
Chairs: Luboš Petruželka, Czech Republic & Surendra Shastri, India

• 11:00 - OA04.01: Educational and Wealth Inequalities in Tobacco Use among Men and Women in 54 Low-And-Middle-Income Countries  
  Chandrashekar Sreeramareddy, Malaysia

• 11:10 - OA04.02: Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial  
  Suresh Ramalingam, USA

• 11:20 - OA04.03: Preliminary Results of a Low Cost Intervention to Improve Tobacco Cessation Practices within a Large University Health System  
  Douglas Arenberg, USA

• 11:30 - OA04.04 Discussant:  
  Gilberto Lopes, Brazil

• 11:45 - OA04.05: Chronic Inflammation, NSAIDS and the Risk of Lung Cancer Death  
  Marisa Bittoni, USA

• 11:55 - OA04.06: Examining Pleiotropic Associations of Genetic Risk Variants for Chronic Obstructive Pulmonary Disease with Lung Cancer Risk  
  Lori Sakoda, USA

• 12:05 - OA04.07: Clinical Characteristics of Lung Adenocarcinoma in the Young: Results from the Genomics of Young Lung Cancer Study  
  Barbara Gitlitz, USA

• 12:15 - OA04.07: Discusssant:  
  Ruxandra Ulmeanu, Romania

11:00 - 12:30: Mini Oral Session (MA01): Improvement and Implementation of Lung Cancer Screening  
Track: Radiology/Staging/Screening  
Room: Lehar 1-2  
Chairs: Michael Studnicka, Austria & Christine Berg, USA

• 11:00 - MA01.01: Detection of Lung Cancer and EGFR Mutations by Electronic Nose System  
  Nir Peled, Israel

• 11:06 - MA01.02: Non-Invasive LuCED® Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with Drugs Such as Iloprost  
  Javier Zulueta, USA

• 11:12 - MA01.03: The Non-Invasive LuCED® Test for Detection of Early Stage Lung Cancer  
  Javier Zulueta, USA

• 11:18 - MA01.04: Discusssant:  
  Jiri Votruba, Czech Republic
• 11:30 - MA01.05: Predictive Performances of NELSON Screening Program Based on Clinical, Metrological and Population Statistics
  Hubert Beaumont, France
• 11:36 - MA01.06: Long-Term Follow-Up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Proper Follow-Up Period and Risk Factors for Subsequent Growth
  Choon-Taek Lee, South Korea
• 11:42 - MA01.07: Influence of Nodule Morphology on Inter-Reader Variability of Volume and Diameter Measurements in CT Lung Cancer Screening
  Marjolein Heuvelmans, Netherlands
• 11:48 - MA01.08: Discussant:
  Ricardo Sales dos Santos, Brazil
• 12:00 - MA01.09: Mortality, Survival and Incidence Rates in the ITALUNG Randomised Lung Cancer Screening Trial (ITALY)
  Eugenio Paci, Italy
• 12:06 - MA01.10: Performance of ACR Lung-RADS in the 1st Brazilian Lung Cancer Screening Trial (BRELT1)
  Ricardo Santos, Brazil
• 12:12 - MA01.11: Implementation of LDCT Lung Cancer Screening into Practice. Results of Regional Early Detection Program
  Maciej Bryl, Poland
• 12:18 - MA01.12: Discussant:
  David Yankelevitz, USA

12:45 - 14:15: Industry Supported Symposia: ISS Immuno-Oncology and Lung Cancer: Emerging Data and Recent Developments - Bristol-Myers Squibb
Room: Hall D (Plenary Hall)
Chair: Matthew Hellmann, USA
• 12:45 - Welcome & Introduction
  Matthew Hellmann, USA
• 12:55 - Developments in the Use of I-O Monotherapy in Lung Cancers
  Enriqueta Felip, Spain
• 13:10 - Rationale for Studying I-O Combo Therapies to Address Unmet Needs in Lung Cancer
  Matthew Hellmann, USA
• 13:35 - Clinical Lessons Learned for the Use of I-O Therapies
  Jürgen Wolf, Germany
• 13:55 - Close & Outlook
  Matthew Hellmann, USA
• 14:00 - Audience Q&A
  Full Panel

14:20 - 15:50: Concurrent Abstract Sessions

14:20 - 15:50: Oral Session (OA05): Treatment Advances in SCLC
Track: SCLC/Neuroendocrine Tumors
Room: Strauss 2
Chairs: Andrea Ardizzoni, Italy & Jean Luis Pujol, France
• 14:20 - OA05.01: Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028
  Patrick Ott, USA
• 14:30 - OA05.02: Anti-Tumor Immunity is a Key Determinant of SCLC Survivorship
  Farhad Kosari, USA
• 14:40 - OA05.03: Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)
  David Spigel, USA
• 14:50 - OA05.04: Discussant: Leora Horn, USA
• 15:05 - OA05.05: Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)
  Taofeek Owonikoko, USA
• 15:15 - OA05.06: Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial
  Marianna Christodoulou, UK
• 15:25 - OA05.07: Prognostic Value of Circulating Tumour Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial
  Fabiola Fernandez-Gutierrez, UK
• 15:35 - OA05.08: Discussant: Jens Benn Sørensen, Denmark

  Track: Biology/Pathology
  Room: Strauss 1
  Chairs: Frances Shepherd, Canada & Yasushi Yatabe, Japan

• 14:20 - OA06.01: Clinical Utility of Circulating Tumor DNA (ctDNA) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients
  Philipp Mack, USA
• 14:30 - OA06.02: Mutational Load Predicts Survival in LDCT Screening-Detected Lung Cancers
  Gabriella Sozzi, Italy
• 14:40 - OA06.04: Transcriptome Analysis of ATM-Deficient NSCLC
  Lars Petersen, Canada
• 14:50 - OA06.05: Discussant: Ross Soo, Singapore
• 15:05 - OA06.05: Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial
  Jean-Charles Soria, France
• 15:15 - OA06.06: Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC)
  Sara Pilotto, Italy
• 15:25 - OA06.07: Evaluating Genomic Signatures Predicting Veliparib Sensitivity in Non-Small Cell Lung Cancer (NSCLC)
  Lei He, USA
• 15:35 - OA06.08: Discussant: Maya Gottfried, Israel

  Track: Surgery
  Room: Stolz 1
Chairs: Vitězslav Kolek, Czech Republic & Tibor Krajc, Austria

- 14:20 - OA07.01: Incidence, Local Distribution and Impact of pN2 Skip Metastasis in Patients Undergoing Curative Resection for NSCLC
  Ariane Steindl, Austria

- 14:30 - OA07.02: Omitting Intrapulmonary Lymph Node Retrieval May Affect the Oncological Outcome of pN0 Lung Cancer Patients: A Propensity Score Match Analysis
  Nan Wu, China

- 14:40 - OA07.03: Prognostic Significance of Micrometastases in Mediastinal Lymph Nodes of Patients With Radically Resected Non-Small Cell Lung Cancer
  Pawel Gwóźdź, Poland

- 14:50 - OA07.04: Discussant:
  Yi Long Wu, China

- 15:05 - OA07.05: Prognostic Impact of Pleural Lavage Cytology (PLC): Significance of PLC after Lung Resection
  Shinya Katsumata, Japan

- 15:15 - OA07.06: In Early-Stage Lung Adenocarcinomas, Survival by Tumor Size (T) is Further Stratified by Tumor Spread through Air Spaces
  Takashi Eguchi, USA

- 15:25 - OA07.07: Discussant:
  Mark Krasnik, Denmark

Track: Biology/Pathology
Room: Stolz 2
Chairs: Elisabeth Brambilla, France & Masayuki Noguchi, Japan

- 14:20 - MA02.01: Extracellular Vesicle miRNAs Regulate Gene Expression in Local Lung Adenocarcinoma Endothelial Cells
  James Lawson, Canada

- 14:26 - MA02.02: A Novel 5-miR Signature Shows Promise as a Diagnostic Tool and as a Predictor of Cisplatin Response in NSCLC
  Martin Barr, Ireland

- 14:32 - MA02.03: Expression of Oncofetal miRNAs Inactivates NFIB, a Developmental Transcription Factor Linked to Tumour Aggressiveness in Lung Adenocarcinoma
  Daiana Becker-Santos, Canada

- 14:38 - MA02.04: Discussant:
  Luis Montuenga, Spain

- 14:50 - MA02.05: Distinct Angiogenic microRNA-mRNA Expression Profiles among Subtypes of Lung Adenocarcinoma
  Mirella Giordano, Italy

- 14:56 - MA02.06: Discussant:
  Rafael Rosell, Spain

- 15:08 - MA02.07: Evaluation of Exosomal miRNAs from Plasma as Potential Biomarker for NSCLC
  Xiance Jin, China

- 15:14 - MA02.08: Deregulation of Cis-Acting Long Non-Coding RNAs in Non-Small Cell Lung Cancer
  Adam Sage, Canada

- 15:20 - MA02.09: Long Non-Coding RNA Expression from Pseudogene Loci as a Novel Mechanism of Cancer Gene Regulation
14:00 - 15:00: Mini Oral (MA03): Epideiology, Risk Factors and Screening
Track: Epidemiology/Tobacco Control and Cessation/Prevention
Room: Lehar 3-4
Chairs: Nazmi Bilir, Turkey & Horst Olschewski, Austria

- 14:20 - MA03.01: Gender Disparities in Non-Small Cell Lung Cancer: A Systematic Review
  Gwyn Bebb, Canada

- 14:26 - MA03.02: Lung Cancer in Women 1929 to 2016: Cold-Blooded Origins of an Epidemic
  Fred Grannis, USA

- 14:32 - MA03.03: High Risk for Second Primary Lung Cancer in Taiwanese Early-Onset Female Breast Cancer Patients
  Pei-Ying Lin, Taiwan

- 14:38 - MA03.04: Discussant:
  Ana Jovicevic, Serbia

- 14:50 - MA03.05: Cost Effectiveness Analysis of CT vs Chest X-Ray (CXR) vs No Screening for Lung Cancer (LC) in the PLCO and NLST Randomized Population Trials (RPTs)
  John Paul Flores, USA

- 14:56 - MA03.06: Cost Effectiveness of Chest Scan Screening for Lung Cancer in Abestos Occupational Exposure Subjects: A Model Based Study
  Christos Chouaid, France

- 14:32 - MA03.07: Discussant:
  Thierry Berghmans, Belgium

- 15:14 - MA03.08: Quantifying Survival in Early-Stage NSCLC: Implications of Relative Survival vs Cause-Specific Survival
  Kay See Tan, USA

- 15:20 - MA03.09: Retrospective Predictive Performance of a Lung Cancer Screening Risk Prediction Model in a Clinical Lung Cancer Screening Program
  Andrea Borondy Kitts, USA

- 15:26 - MA03.10: Educational Level and the Management and Outcome in Non-Small Cell Lung Cancer: A Nationwide Study (Sweden)
  Anna Öjdahl Boden, Sweden

- 15:32 - MA03.11: Discussant:
  Oleg Pikin, Russia

14:30 - 15:15: Meet the JTO Editor
Room: Schubert 4
Chair: Alex Adjei, USA

14:30 - 15:45: Educational Session (ED03): Global Tobacco Control Policies: Advances & Challenges
Track: Epidemiology/Tobacco Control and Cessation/Prevention
Room: Hall C1
Chairs: Gábor Kovács, Hungary & Xiuyi Zhi, China

- 14:30 - Tobacco Control in the Middle East
  Feras Hawari, Jordan

- 14:50 - The Australian Tobacco Control Strategy: Lessons Learned
  Mike Daube, Australia
• 15:10 - Tobacco Control and Lung Cancer in Africa
  Lekan Ayo-Yusuf, South Africa
• 15:30 - Trumping Big Tobacco
  Bronwyn King, Australia

14:30 - 15:45: Educational Session (ED04): Bronchopulmonary Carcinoids
Track: SCLC/Neuroendocrine Tumors
Room: Lehar 1-2
Chairs: Vera Gorbunova, Russia & Jörg Hutter, Austria

• 14:30 - Surgery in Bronchopulmonary Typical and Atypical Carcinoids
  Pier Luigi Filosso, Italy
• 14:50 - Systemic Therapy of Bronchopulmonary Typical and Atypical Carcinoids: Current Status and Perspectives
  Eric Baudin, France

14:30 - 15:45: Interactive Session (IA03): What are the Lung Cancer Patients Needs in the Different Countries?
Track: Patient Support and Advocacy Groups (Interactive Session)
Room: Schubert 2
Chairs: Stefania Vallone, Italy, Ingeborg Beunders, Austria & Nelly Enwerem-Bromson, Austria

Patient needs around the world. Participants will place notes showing the needs in the countries on a map, which will be followed by a discussion. Outcome of the interactive session will be presented at the end of the conference by Stefania Vallone and Ingeborg Beunders.

14:30 - 15:45: Pro-Con Session (PC01): Invasive Mediastinal Staging for N2 Disease
Track: Radiology/Staging/Screening | Locally Advanced NSCLC
Room: Hall C2
Chairs: Walter Weder, Switzerland & Helmut Prosch, Austria

• 14:30 - Introduction & Vote
  Helmut Prosch, Austria
• 14:40 - Invasive Staging and Restaging
  Christophe Dooms, Belgium
• 15:00 - No Invasive Staging Nor Restaging
  Eric Lim, UK
• 15:20 - Discussion & Vote
  Walter Weder, Switzerland

14:30 - 15:45: Science Session (SC06): Novel Therapies in Malignant Pleural Mesothelioma and Thymic Malignancies
Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
Room: Strauss 3
Chairs: Anna Nowak, Australia & Takashi Nakano, Japan

• 14:30 - Comprehensive Genomic Analysis of Malignant Pleural Mesothelioma
  Raphael Bueno, USA
• 14:50 - Stratified Therapy for Malignant Pleural Mesothelioma
  Dean Fennel, UK
• 15:10 - Intraoperative Therapies in Malignant Pleural Mesothelioma
14:30 - 15:45: Poster Session with Presenters Present (P1)
Room: Hall B (Poster Area)
- Click here for the 17th IASLC WCLC Poster Program >>

16:00 - 17:00: Educational Session (ED05): The 8th Edition of the TNM Staging System
Track: Radiology/Staging/Screening
Room: Hall C1
Chairs: Peter Goldstraw, UK & Ramon Rami-Porta, Spain
- 16:00 - What's New in Lung Cancer Staging?
  Hisao Asamura, Japan
- 16:25 - Update on the Mesothelioma Staging System
  Valerie Rusch, USA
- 16:45 - The Thymic Epithelial Tumor Staging System
  Kazuya Kondo, Japan
- 17:05 - What's New in Esophageal Cancer Staging?
  Thomas Rice, USA

16:00 - 17:30: Educational Session (ED06): Symptom Management in Lung Cancer
Track: Palliative Care/Ethics
Room: Stolz 1
Chairs: Richard Gralla, USA & Reza Malayeri, Iran
- 16:00 - Causes and Management of Dyspnea
  Otto Burghuber, Austria
- 16:15 - Endobronchial and Pleural Palliation
  Arschang Valipour, Austria
- 16:30 - Pain Management
  Vera Hirsh, Canada
- 16:45 - Biology and Management of Tumor Cachexia
  Jeffrey Crawford, USA
- 17:00 - Surgery for Symptom Relief
  Shahrokh Taghavi, Austria
- 17:15 - Decisions in Case of Intractable Symptoms
  Jean Klastersky, Belgium

16:00 - 17:30: Science Session (SC07): New Challenges for Lung Cancer: Waterpipes and E-Cigarettes
Track: Epidemiology/Tobacco Control and Cessation/Prevention
Room: Stolz 2
Chairs: Martina Pötschke-Langer, Germany & Manfred Neuberger, Austria
- 16:00 - Carcinogen Exposure from Waterpipe and ENDS (Electronic Nicotine Delivery Systems)
Alan Shihadeh, Lebanon
- 16:25 - Health Effects of E-Cigarette Aerosol and Nicotine Exposure on the Respiratory System
  Charlotta Pisinger, Denmark
- 16:50 - Connections of Nicotine to Cancer and its Influence on Cancer Treatment
  Sergei Grando, USA
- 17:15 - Q&A

16:00 - 17:30: Science Session (SC08): IASLC-ESTS Joint Symposium: The Borderline Patient
Track: Surgery | Pulmonology
Room: Hall C7
Chairs: Jaroslaw Kuzdzal, Poland & Hans Hoffmann, Germany

- 16:00 - Impact and Management of Co-Morbidities
  Alessandro Brunelli, UK
- 16:20 - Emphysema as a Limiting Factor for Lung Resection: How Far We Can Go?
  Walter Weder, Switzerland
- 16:40 - Surgical Issues in the Borderline Patient: Sublobar versus Standard Resection
  David Harpole, USA
- 17:00 - SABR Versus Surgery
  Norihiko Ikeda, Japan
- 17:20 - Q&A

16:00 - 17:30: Science Session (SC09): Radiotherapy for a Global Cancer
Track: Radiotherapy | Regional Aspects/Health Policy/Public Health
Room: Hall C8
Chairs: Yuko Nakayama, Japan & Deniz Yalman, Turkey

- 16:00 - Global Access To Radiotherapy: Are We There?
  David Palma, Canada
- 16:20 - The Quest for High Quality Affordable Radiotherapy in Developing Countries
  Hak Choy, USA
- 16:40 - Machine Learning for Individualized Radiotherapy Prescription
  Phillippe Lambin, The Netherlands
- 17:00 - Radiotherapy in China
  Luhua Wang, China
- 17:20 - Q&A

16:00 - 17:30: Science Session (SC10): Squamous Cell NSCLC
Track: Chemotherapy/Targeted Therapy/Immunotherapy | Advanced NSCLC
Room: Strauss 3
Chairs: David Gandara, USA & Martin Sebastian, Germany

- 16:00 - Genetic Alterations as Potential Therapeutic Targets
  Roman Thomas, Germany
- 16:20 - EGFR Mutations in Indian Patients with Squamous Cell NSCLC
  Kumar Prabhash, India
- 16:40 - Anti-EGFR Monoclonal Antibodies in Squamous Cell NSCLC
  Robert Pirker, Austria
- 17:00 - Second-Line Therapy and Beyond in Squamous Cell NSCLC
  Silvia Novello, Italy
17:20 - Q&A

16:00 - 17:30: Science Session (SC11) ALK, ROS1 and Rare Mutations in NSCLC
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Lehar 1-2
Chairs: Dong-Wan Kim, South Korea & Dragana Jovanovic, Serbia

- 16:00 - Optimal Application & Sequence of ALK Inhibition Therapy
  Benjamin Solomon, Australia
- 16:20 - Resistance to ALK Inhibitor Therapy
  Sai-Hong Ou, USA
- 16:40 - ROS1 as a Therapeutic Target in Advanced NSCLC
  Jürgen Wolf, Germany
- 17:00 - Rare Mutations in Lung Cancer
  Oliver Gautschi, Switzerland
- 17:20 - Q&A

16:00 - 17:30: Science Session (SC12): Anticancer Drug Development in the 21st Century
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C2
Chairs: Lawrence Einhorn, USA & Kaoru Kubota, Japan

- 16:00 - Establishment of EGFR Tyrosine Kinase Inhibitors: History and Lessons Learned for Future Drug Development
  Tony Mok, Hong Kong
- 16:25 - Molecular-Based Therapy of Lung Cancer: The Way Forward?
  Charles Rudin, USA
- 16:45 - Implications of Patient Selection: Are we Lost in Diversification?
  Yu Shyr, USA
- 17:05 - Drug Development: The EMA Perspective
  Francesco Pignatti, UK
- 17:25 - Q&A

16:00 - 17:30: Interactive Session (IA04): Target Delineation* (Ticketed Session: €35,00)
Track: Radiotherapy
Room: Schubert 3
Coordinators: Karin Dieckmann, Austria & Helmut Prosch, Austria
Group I (Space is limited to 20 participants)
Trainers: Corinne Faivre-Finn, UK, Laurie Gaspar, USA, Billy Loo, USA
*Please note that this session is a duplicate of the session on Tuesday

16:00 - 17:30: Nurses Session (NU02): Preparing Patients for Treatment
Track: Nurses
Room: Schubert 5
Chairs: Diana Borthwick, UK & Anne Fraser, New Zealand

- 16:00 - Preparing Patients for Treatment. Providing Psychosocial Support for Lung Cancer Patients Preparing to Enter Treatment
  Andreja Cirila Škufca Smrdel, Slovenia
- 16:20 - Preoperative Thoracic Surgery Patient Education Program Development
  Katherine Kuhns, USA
- 16:40 - Ethical Decision Making
16:00 - 17:30: Patient Advocacy Session (PA02): Access to Care - Equal Chances in the World?
Track: Patient Support and Advocacy Groups
Room: Schubert 6
Chairs: Christina Ng, Malaysia & Shani Shilo, Israel

- 16:00 - Access to Care: USA
  Kim Norris, USA
- 16:15 - Access to Care: South America
  Patricia Mondragon, Mexico
- 16:30 - Access to Care: Malaysia
  Christina Ng, Malaysia
- 16:45 - Access to Care: Europe
  Juan Fuertes, Spain
- 17:00 - Access to Care: Australia
  Kerrie Callaghan, Australia
- 17:15 - Access to Care: Israel
  Shani Shilo, Israel

16:00 - 17:30: Concurrent Abstract Sessions

16:00 - 17:30: Oral Session (OA08): Targeted Therapies in Brain Metastases
Track: Advanced NSCLC
Room: Schubert 1
Chairs: David Ball, Australia & TBD

- 16:00 - OA08.01: Exploration of the Underlying Mechanisms of Leptomeningeal Metastasis in NSCLC Patients through NGS of Cerebrospinal Fluid
  Yun Fan, China
- 16:10 - OA08.02: Phase II Study of Erlotinib in Advanced Non-Small Cell Lung Cancer Patients with Leptomeningeal Metastasis (LOGIK1101)
  Keiichi Ota, Japan
- 16:20 - OA08.03: MET Copy Number Gain Associates with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR Mutant Lung Cancer
  Seiji Yano, Japan
- 16:30 - OA08.04: Discussant:
  Roman Perez-Soler, USA
- 16:45 - OA08.05: Efficacy and Cerebrospinal Fluid Concentration of Afatinib in NSCLC Patients with EGFR Mutation Developing Leptomeningeal Carcinomatosis
  Akihiro Tamiya, Japan
- 16:55 - OA08.06: Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials
  Scott Gettinger, USA
- 17:05 - OA08.07: BRAF-V600E Advanced Lung Adenocarcinoma with Leptomeningeal (LM) Disease Treated with Vemurafenib
  Maria Gabriela Fernandes, Portugal
- 17:15 - OA08.08: Discussant:
  Niels Reinmuth, Germany
16:00 - 17:30: Mini Oral Session (MA04): HER2, P53, KRAS and Other Targets in Advanced NSCLC  
Track: Advanced NSCLC  
Room: Lehar 3-4  
Chairs: Baohui Han, China & Wolfgang Hilbe, Austria  

- **16:00 - MA04.01:** Non-Amplification Mutation of ERBB2 in EGFR-Mutated Lung Cancer  
  Jeffrey Ross, USA  
- **16:06 - MA04.02:** Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study  
  Leena Gandhi, USA  
- **16:12 - MA04.03:** Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC  
  Shengxiang Ren, China  
- **16:18 - MA04.04:** Discussant:  
  Thanyanan Reungwetwattana, Thailand  
- **16:30 - MA04.05:** P53 Non-Disruptive Mutation is a Negative Predictive Factor for OS and PFS in EGFR M+ NSCLC Treated with TKI  
  Frank Griesinger, Germany  
- **16:36 - MA04.06:** Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoresponse, Inflammation and DNA Repair  
  Sara Baglivo, Italy  
- **16:42 - MA04.07:** Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy  
  Ferdinados Skoulidis, USA  
- **16:48 - MA04.08:** Discussant:  
  Julian Molina, USA  
- **17:00 - MA04.09:** RICTOR Amplification in Non-Small Cell Lung Cancer: An Emerging Therapy Target  
  Jefffrey Ross, USA  
- **17:06 - MA04.10:** Lung Cancer Growth is Suppressed by CD26/DPP4-Inhibition via Enhanced NK Cell and Macrophage Recruitment  
  Jae-Hwi Jang, Switzerland  
- **17:12 - MA04.11:** Mechanistic Insights into CAR T-Cell Efficacy in the Treatment of Heterogenous Antigen Expressing Lung Adenocarcinoma  
  Prasad Adusumilli, USA  
- **17:18 - MA04.12:** Discussant:  
  Ales Ryska, Czech Republic  

16:00 - 17:30: Mini Oral Session: (MA05): Innovative Techniques in Pulmonology and the Impact on Lung Cancer  
Track: Pulmonology  
Room: Strauss 1  
Chairs: Josef Eckmayr, Austria & Prasanta R. Mohapatra, India  

- **16:00 - MA05.01:** Virtual Bronchoscopic Navigation-Guided Ultrathin Bronchoscopy for Diagnosing Peripheral Pulmonary Lesions  
  Marta Diez-Ferrer, Spain  
- **16:06 - MA05.02:** Electromagnetic Navigation Bronchoscopy: A Prospective, Global, Multicenter Analysis of 1000 Subjects with Lung Lesions  
  Sandeep Khandhar, USA
• 16:06 - MA05.03: A Single EBUS-TBNA Pass Yields Sufficient DNA for Targeted Molecular Testing in Lung Cancer
   Tracy Leong, Australia

• 16:12 - MA05.04: Discussant:
   Vítězslav Kolek, Czech Republic

• 16:30 - MA05.05: Genomic Profiles of Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
   Ji An Hwang, South Korea

• 16:36 - MA05.06: Diagnosis of Chronic Obstructive Pulmonary Disease in Lung Cancer - A Population Based Study
   John Goffin, Canada

• 16:42 - MA05.07: Identifying Comorbid Disease on Chest CT Scans in a Lung Cancer Screening-Eligible Cohort
   James Finigan, USA

• 16:48 - MA05.08: Discussant:
   Konstantinos Zarogoulidis, Greece

• 17:00 - MA05.09: There is a Closely Relation between Exhaled Nitric Oxide and Radiation Pneumonitis
   Jiancheng Li, China

• 17:06 - MA05.10: Cell-Free DNA Testing for EGFR Mutations in Clinical Practice - Facts and Figures from an Austrian Lung Cancer Center
   David Lang, Austria

• 17:12 - MA05.11: Photodynamic Therapy for Peripheral Lung Cancer Using Composite-Type Optical Fiberscope of 1.0 Mm in Diameter
   Jitsuo Usuda, Japan

• 17:18 - MA05.12: Discussant:
   Judit Moldvay, Hungary

16:00 - 17:30: Mini Oral Session (MA06): Locally Advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices
Track: Locally Advanced NSCLC
Room: Strauss 2
Chairs: Paul Van Houtte, Belgium & Milada Zemanova, Czech Republic

• 16:00 - MA06.01: Overall Survival Characterization of Incidental N2 Non-Small Cell Lung Cancer over 14 Years at a Single Canadian Institution
   Cara Van Der Merwe, Canada

• 16:06 - MA06.02: Does Pathological Staging Following Neoadjuvant Therapy (ypTNM) Reflect the Reality?
   Huseyin Melek, Turkey

• 16:12 - MA06.03: Recurrence Dynamics after Trimodality Therapy (Neoadjuvant Chemoradiotherapy and Surgery) in Stage IIIa(N2) Lung Cancer
   Jung Hee Lee, South Korea

• 16:18 - MA06.04: Discussant:
   Fan Yang, China

• 16:30 - MA06.05: Screening for Brain Metastases in Patients with Stage III NSCLC, MRI or CT? A Prospective Study
   Janna Schoenmaekers, Netherlands

• 16:36 - MA06.06: Tumor Microenvironment and Brain Metastases in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
   Qin Zhang, China
- 16:42 - MA06.07: Impact of Type 2 Diabetes Mellitus and Its Metabolic Control on Prognosis of Unresectable Non-Small Cell Lung Cancer Patients
  Milana Bergamino Sirvén, Spain

- 16:48 - MA06.08: Discussant:
  Miroslaw Kozlowski, Poland

- 17:00 - MA06.09: Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin & Chemo-Radiation in Stage III NSCLC. SLCG 10/02
  Dolores Isla, Spain

- 17:06 - MA06.10: A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC
  Thomas Stinchcombe, USA

- 17:12 - MA06.11: Phase II Study of Nimotuzumab + Concurrent Chemoradiotherapy (CRT) for Stage III Non-Small Cell Lung Cancer (NSCLC): 5-Year Follow-Up Results
  Kazushige Hayakawa, Japan

- 17:18 - MA06.12: Discussant:
  Philip Bonomi, USA

17:45 - 19:15: Industry Supported Symposium: ISS Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus on EGFR-Targeted Therapy - A prIME Oncology satellite symposium supported by Boehringer Ingelheim Pharma GmbH & co. KG
Room: Hall C7
Chair: Martin Schuler, Germany

- 17:45 - Welcome & Warm-up Quiz
  Martin Schuler, Germany

- 17:50 - Key Decision Points for Personalized Patient Care of Advanced Non-Small Cell Lung Cancer (NSCLC)
  Martin Schuler, Germany

- 18:00 - Managing EGFR-Mutant Adenocarcinoma: What is the Optimal First-Line Approach?
  Barbara Melosky, Canada

- 18:20 - Tackling Acquired Resistance to EGFR-Targeted Therapy: Evaluating Current and Emerging Treatment Strategies
  Keunchil Park, South Korea

- 18:40 - Contemporary Management of Squamous Cell Carcinoma: What is the Role of EGFR-Targeted Therapy in the Era of Immunotherapy?
  Marianne Nicolson, UK

- 18:55 - Quiz Questions Revisited and Questions from the Audience
  Martin Schuler, Germany

- 19:10 - prIME Points™
  Martin Schuler, Germany
Tuesday, December 6, 2016

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH03)
Tracks: Early Stage NSCLC
Locally Advanced NSCLC
Surgery
Room: Hall C1
Chairs: Walter Klepetko, Austria & Mark Krasnik, Denmark

- **Surgery:**
  Saulus Cicenas, Lithuania
- **NSCLC stage I-II:**
  Elie Fadel, France
- **NSCLC stage III:**
  Virginie Westeel, France

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH04)
Tracks: Radiology/Staging/Screening
Pulmonology
Room: Hall C7
Chairs: Jiri Votruba, Czech Republic & Sylvia Hartl, Austria

- **Screening:**
  James Jett, USA
- **Radiology/Staging:**
  Wilfried Eberhardt, Germany
- **Pulmonology:**
  Edgar Smit, The Netherlands

07:30 - 08:30: Meet the Expert (MTE10) (Ticketed Session: €35,00)
Track: Biology/Pathology
Room: Schubert 1
- **Unique Biologic Aspects of Tobacco-Induced Lung Cancer**
  Mauro Papotti, Italy

07:30 - 08:30: Meet the Expert (MTE11) (Ticketed Session: €35,00)
Track: Biology/Pathology
Room: Schubert 2
- **The Clinical Impact of the 2015 WHO Classification of Lung Tumors**
  Andrew Nicholson, UK & Masayuki Noguchi, Japan

07:30 - 08:30: Meet the Expert (MTE12) (Ticketed Session: €35,00)
Track: Biology/Pathology
Room: Schubert 4
- **Clinically Relevant Signal Transduction Pathways**
  Ming-Sound Tsao, Canada & Balazs Dome, Austria

07:30 - 08:30: Meet the Expert (MTE13) (Ticketed Session: €35,00)
Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy
Room: Schubert 5
- **Basic Immunology for the Clinician**
  Marcin Moniuszko, Poland & Edgardo Santos, USA

07:30 - 08:30: **Meet the Expert (MTE14)** (Ticketed Session: €35,00)
Track: Radiology/Staging/Screening
Room: Schubert 6
  - **How to Implement Screening/Early Detection in Routine Practice**
    Harry J De Koning, The Netherlands & Sam Janes, UK

07:30 - 08:30: **Meet the Expert (MTE15)** (Ticketed Session: €35,00)
Track: Radiology/Staging/Screening | Surgery
Room: Strauss 1
  - **Lymph Node Mapping in Lung Cancer**
    Kenji Suzuki, Japan & David Waller, UK

07:30 - 08:30: **Meet the Expert (MTE16)** (Ticketed Session: €35,00)
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Strauss 2
  - **Precision Medicine in NSCLC: Lessons Learned and Perspectives**
    Christian Manegold, Germany & Terufumi Kato, Japan

07:30 - 08:30: **Meet the Expert (MTE17)** (Ticketed Session: €35,00)
Track: Advanced NSCLC | Chemotherapy/Targeted Therapy/Immunotherapy
Room: Strauss 3
  - **Maintenance Therapy Versus Early Second-Line Therapy in Advanced NSCLC**
    Tudor Ciuleanu, Romania & Panos Fidias, USA

07:30 - 08:30: **Meet the Expert (MTE18)** (Ticketed Session: €35,00)
Track: SCLC/Neuroendocrine Tumors
Room: Lehar 1-2
  - **Perspectives in the Systemic Treatment of Small-Cell Lung Cancer**
    Mary O’Brien, UK & Pieter Postmus, UK

07:30 - 08:30: **Meet the Expert (MTE19)** (Ticketed Session: €35,00)
Track: Chemotherapy/Targeted Therapy/Immunotherapy | Trial Design/Statistics
Room: Stolz 1
  - **Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice**
    Richard Gralla, USA & Kostas Syrigos, Greece

07:30 - 08:30: **Meet the Expert (MTE20)** (Ticketed Session: €35,00)
Track: Radiotherapy
Room: Stolz 2
  - **Radiotherapy of Locally Advance NCSLC: Selecting the Right Patient for the Right Radiotherapy**
    Dirk De Ruysscher, The Netherlands

07:30 - 08:30: **Industry Supported Symposium: ISS Targeted Therapy on the Horizon for SCLC - AbbVie**
Room: Lehar 3-4
Chair: Martin Reck, Germany
• 07:30 - Challenges in SCLC Across Decades
  Martin Reck, Germany
• 07:40 - Advancing the Study in SCLC - What is the Underlying Biology?
  Jean-Charles Soria, France
• 07:55 - Emerging Novel Agents - A New Day for SCLC Treatment
  Ramaswamy Govindan, USA
• 08:15 - Panel Discussion: Looking Over the Horizon - Future Treatment of SCLC
  All Faculty
• 08:25 - Question & Answer
  All Faculty

08:35 - 10:25: Plenary Session (PL03): Presidential Symposium
Room: Hall D (Plenary Hall)  
Chairs: David Carbone, USA & Robert Pirker, Austria

• 08:35 - PL03.01: Presidential Address
  David Carbone, USA
• 08:45 - PL03.02: Lung Cancer Staging - Changing the Clinical Practice
  Ramon Rami-Porta, Spain
• 09:05 - PL03.03: Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3)
  Vassiliki Papadimitrakopoulou, USA
• 09:15 - PL03.04: Discussant
  Tetsuya Mitsudomi, Japan
• 09:25 - PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)
  Yi Long Wu, China
• 09:35 - PL03.06: Discussant:
  Jacek Jassem, Poland
• 09:45 - PL03.07: First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
  Gilberto De Castro Jr, Brazil
• 09:55 - PL03.08: Discussant:
  Fiona Blackhall, UK
• 10:05 - PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2)
  Rathi Pillai, USA
• 10:15 - PL03.10: Discussant:
  David Gandara, USA

10:25 - 10:55: Exhibit Showcase Session: Boehringer Ingelheim
Room: Hall B (Exhibit Showcase Theater)

Giotrif: 10 Reasons to Use Afatinib in Lung Cancer
Vargatef: Providing Benefits Even Where you May Not Expect It

10:30 - 11:00: Poster Session
Room: Hall B (Poster Area)

10:30 - 11:45: Press Conference (PR03): Accurate Diagnosis
Room: Schubert 1
Chairs: Heather Wakelee, Stanford Cancer Institute, USA

- **PR03.01**: Lung Cancer Staging - Changing the Clinical Practice - Ramon Rami-Porta, Hospital Universitari Mutua Terrassa, and CIBERES Lung Cancer Group, Spain
- **PR03.02**: Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3) - Vassiliki Papadimitrakopoulou, MD Anderson Cancer Center, USA
- **PR03.03**: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201) - Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China
- **PR03.04**: First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4) - Gilberto De Castro Jr, Instituto do Câncer do Estado de São Paulo - ICESP, Brazil

**11:00 - 12:30: Educational Session (ED07): Classification and Druggable Targets of Thoracic Tumors**

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: Hall C1

Chairs: Adi Gazdar, USA & Helmut Popper, Austria

- **11:00**: Adenocarcinomas and Squamous Cell Carcinomas
  William Travis, USA
- **11:20**: The 2015 WHO Classification of Neuroendocrine Tumors
  Elisabeth Brambilla, France
- **11:40**: The 2015 WHO Classification of Tumors of the Pleura
  Richard Attanoos, UK
- **12:00**: The WHO Classification of Thymomas and Thymic Carcinomas
  Alexander Marx, Germany
- **12:20**: Q&A

**11:00 - 12:30: Science Session (SC13): Interaction of COPD and Lung Cancer - Consequences for Early Diagnosis and Management**

Track: Radiology/Staging/Screening | Pulmonology

Room: Stolz 1

Chairs: Anne-Pascale Meert, Belgium & Konstantinos Zarogoulidis, Greece

- **11:00**: Common Pathogenesis of COPD and Lung Cancer
  Kwun Fong, Australia
- **11:20**: Increased Risk for Lung Cancer in COPD
  Stephen Lam, Canada
- **11:40**: Limitation by COPD for Diagnostic Procedures
  Gyula Ostoros, Hungary
- **12:00**: Limitations by COPD for Treatment
  Yoichi Nakanishi, Japan
- **12:20**: Q&A

**11:00 - 12:30: Science Session (SC14): Immunotherapy of NSCLC**

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: Hall C2

Chairs: Naiyer Rizvi, USA & Christoph Zielinski, Austria
11:00 - Immunotherapy in the First-Line Setting of Advanced NSCLC
Roy Herbst, USA

11:20 - Immunotherapy in the Second-Line Setting of Advanced NSCLC
Luis Paz-Ares, Spain

11:40 - Combination Immunotherapy - Basic Considerations and First Outcomes
David Spigel, USA

12:00 - The CD47 Macrophage Checkpoint as a New Immunotherapy Target
Branimir Sikic, USA

12:15 - Tobacco Use and Immunotherapy
Anne-Marie Dingemans, The Netherlands

11:00 - 12:30: Science Session (SC15): Clinical Trials: How to set Priorities?
Track: Trial Design/Statistics
Room: Hall C8
Chairs: Rolf Stahel, Switzerland & Yi Long Wu, China

- 11:00 - The American Perspective
  Suresh Ramalingam, USA
- 11:15 - The European Perspective
  Rolf Stahel, Switzerland
- 11:30 - The Chinese Perspective
  Yi Long Wu, China
- 11:45 - The Japanese Perspective
  Yuichiro Ohe, Japan
- 12:00 - The South American Perspective
  Gilbert Castro, Brazil
- 12:15 - Q&A

11:00 - 12:30: Interactive Session (IA05): The Practical use of the TNM Classifications for Thoracic Cancers
Track: Radiology/Staging/Screening
Room: Hall C7
Chairs: Hisao Asamura, Japan & Christian Herold, Austria

- 11:00 - Lung Cancer Cases
  Gustavo Lyons, Argentina
- 11:30 - Mesothelioma Cases
  Mir Hoda, Austria
- 11:50 - Thymic Carcinoma Cases
  Frank Detterbeck, USA
- 12:10 - Esophageal Carcinoma Cases
  Thomas Rice, USA

11:00 - 12:30: Interactive Session (IA06): Staging* (Ticketed session: €35,00)
Group II (Space is limited to 20 participants)
Track: Radiology/Staging/Screening
Room: Schubert 3
Coordinators: Karin Dieckmann, Austria & Helmut Prosch, Austria
Trainers: Libor Havel, Czech Republic, Anna Kerpel-Fronius, Hungary & Elisabeth Stiefsohn, Austria
*Please note that this session is a duplicate of the session on Monday
11:00 - 12:30: Nurses Session (NU03): Supporting Patients Receiving Treatment
Track: Nurses
Room: Schubert 5
Chairs: Vanessa Beattie, UK & Mary Duffy, Australia

- 11:00 - Supporting Patients Undergoing Radical Treatments EPD - MARS Study
  Angela Tod, UK
- 11:20 - eHealth and Remote Patient Monitoring and Supportive Care in Thoracic Oncology
  Roma Maguire, UK
- 11:40 - Supportive Care in Patients Receiving Systemic Therapy
  Tanja Čufer, Slovenia
- 12:00 - Q&A

11:00 - 12:30: Patient Advocacy Session (PA03): Patient Support and Involvement in Research
Track: Patient Support and Advocacy Groups
Room: Schubert 6
Chairs: Jennifer King, USA & Pawel Moszumanski, Poland

- 11:00 - Central European Lung Cancer Patient Network (CELCAPANET)
  Franz Buchberger, Austria
- 11:15 - Psycho-Social and Communication Needs of Cancer Patients: Romanian Results
  Csaba László Dégi, Romania
- 11:30 - How to Live with Lung Cancer? The Slovenian Lung Cancer Patient Support
  Andreja Škufca Smrđel, Slovenia
- 11:45 - Patient Involvement in the Evaluation of Cancer Medicines: The EMA Experience
  Nathalie Bere, UK

11:00 - 12:30: Concurrent Abstract Sessions

11:00 - 12:30: Oral Session (OA09): Locally Advanced NSCLC: Innovative Treatment Strategies
Track: Locally Advanced NSCLC
Room: Strauss 3
Chairs: Walter Curran, USA & Myung-Ju Ahn, South Korea

- 11:00 - OA09.01: The Number or the Position is the Main Prognostic Factor for N2 NSCLC? A Validation of New IASLC N Staging Proposal
  Sara Ricciardi, Italy
- 11:10 - OA09.02: Should Surgery Be Part of the Multimodality Treatment for Stage IIIB Non-Small Cell Lung Cancer
  Stephane Collaud, France
- 11:20 - OA09.03: Randomized Controlled Study Comparing Adjuvant versus Neo-Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC
  Yi Long Wu, China
- 11:30 - OA09.04: Discussant:
  Masahiro Tsuboi, Japan
- 11:45 - OA09.05: Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (FAZA) to Assess Tumor Hypoxia in Non-Small Cell Lung Cancer (NSCLC)
  Alexander Sun, Canada
- 11:55 - OA09.06: Metformin Use during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
  Krista Wink, Netherlands
12:05 - OA09.07: Individual Isotoxic RT Dose Escalation Based on V20 and Advanced Technologies Benefit Stage III NSCLC Treated with CCRT
Baosheng Li, China

12:15 - OA09.08: Discussant:
Paul van Houtte, Belgium

11:00 - 12:30: Oral Session (OA10): EGFR Mutations
Track: Biology/Pathology
Room: Strauss 1
Chairs: James Spicer, UK & Terufumi Kato, Japan

- 11:00 - OA10.01: Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade
  Jonathan Riess, USA
- 11:10 - OA10.02: Association of Variations in HLA-Class II and Other Loci with Susceptibility to EGFR-Mutated Lung Adenocarcinoma
  Takashi Kohno, Japan
- 11:20 - OA10.03: YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer
  Rafael Rosell, Spain
- 11:30 - OA10.04: Discussant:
  Hossein Borghaei, USA
- 11:45 - OA10.05: EGFR Gene Mutations Affect Tumor-Infiltrating Stromal Cell Components in Early-Stage Lung Adenocarcinoma
  Toshiyuki Shima, Japan
- 11:55 - OA10.06: Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study)
  Julien Mazieres, France
- 12:05 - OA10.07: Report on Liquid Biopsies from Advanced Lung Adenocarcinoma Patients and Correlation with Their Tumor Biopsy Profiles
  Edgardo Santos, USA
- 12:15 - OA10.08: Discussant:
  Frederico Cappuzzo, Italy

11:00 - 12:30: Oral Session (OA11): Angiogenesis in Advanced Lung Cancer
Track: Advanced NSCLC
Room: Stolz 2
Chairs: Luis Montuenga, Spain & John Heymach, USA

- 11:00 - OA11.01: Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study
  Alexis Cortot, France
- 11:10 - OA11.02: Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results
  Kazuhiko Nakagawa, Japan
- 11:20 - OA11.03: A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer
  Shun Lu, China
- 11:30 - OA11.04: Discussant:
  Maurice Perol, France
11:45 - OA11.05: A Phase 2 Study of Cabozantinib for Patients with Advanced RET-Rearranged Lung Cancers  
Alexander Drilon, USA

11:55 - OA11.06: Role of Fibroblasts in the Subtype-Specific Therapeutic Effects of Nintedanib in Non-Small Cell Lung Cancer (NSCLC)  
Jordi Alcaraz, Spain

12:05 - OA11.07: Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer  
Sha Zhao, China

12:15 - OA11.08: Discussant:  
Rainer Wiewrodt, Germany

11:00 - 12:30: Oral Session (OA12): SBRT and Other Issues in Early Stage NSCLC  
Track: Early Stage NSCLC  
Room: Strauss 2  
Chairs: Dirk De Ruyscher, The Netherlands & Michael Rolf Mueller, Austria

- OA12.01: Phase II Randomized Study of 2 SBRT Regimens for Medically Inoperable Patients with Node Negative Peripheral NSCLC  
Jorge A. Gomez Suescun, USA

- OA12.02: Excellent Survival Achieved by Stereotactic Body Radiotherapy for Medically Operable and Young (< 75 Years) Patients with Stage I Lung Cancer  
Hiroshi Onishi, Japan

- OA12.03: Percutaneous Cryoablation for Lung Cancer Patients for Whom Surgery or Radiotherapy is Contraindicated Due to Idiopathic Pulmonary Fibrosis  
Takashi Ohtsuka, Japan

- OA12.04: Discussant:  
Matthias Guckenberger, Switzerland

- OA12.05: Noninvasive CT-Based Image Biopsy System (iBiopsy) for Early Stage Lung Adenocarcinoma  
Dawei Yang, China

- OA12.06: A Retrospective Analysis of Patients with Small Lung Adenocarcinoma (≤2cm) by New World Health Organization Classification  
Keita Nakao, Japan

- OA12.07: Selection for Adjuvant Chemotherapy in Stage IB Non-Small Cell Lung Cancer: A Propensity Score-Matched Analysis  
Jae Hyun Jeon, South Korea

- OA12.08: Discussant:  
Ryuichi Waseda, Japan

11:00 - 12:30: Mini Oral Session (MA07): ALK-ROS1 in Advanced NSCLC  
Track: Advanced NSCLC  
Room: Lehar 1-2  
Chairs: Navneet Singh, India & Jürgen Wolf, Germany

- MA07.01: Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC  
Sai-Hong Ignatious Ou, USA

- MA07.02: Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer  
Shirish Gadgeel, USA
• 11:12 - MA07.03: Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)  
  Young Kim, Japan
• 11:18 - MA07.04: Discussant:  
  Benjamin Besse, France
• 11:30 - MA07.05: EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results  
  Sebastian Michaels, Germany
• 11:36 - MA07.06: Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Preliminary Results of the METROS Trial  
  Lorenza Landi, Italy
• 11:42 - MA07.07: Ceritinib in ROS1-Rearranged Non-Small-Cell Lung Cancer: An Update of Korean Nationwide Phase II Study  
  Byoung Chul Cho, South Korea
• 11:48 - MA07.08: Discussant:  
  Enriqueta Felip, Spain
• 12:00 - MA07.09: Mass Spectrometry Profiling and Imaging Platform for Novel Precision Drug Resistance Biomarkers in EML4-ALK Lung Adenocarcinoma  
  Patrick Ma, USA
• 12:06 - MA07.10: HDAC Inhibition Overcomes Crizotinib-Resistance by Mesenchymal-Epithelial Transition (MET) in EML4-ALK Lung Cancer Cells  
  Koji Fukuda, Japan
• 12:12 - MA07.11: Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC)  
  E Felip, Spain
• 12:18 - MA07.12: Discussant:  
  Robert Doebele, USA

11:00 - 12:30: Mini Oral Session (MA08): Treatment Monitoring in Advanced NSCLC
Track: Advanced NSCLC
Room: Lehar 3-4
Chairs: Roman Perez-Soler, USA & Thanyanan Reungwetwattana, Thailand

• 11:00 - MA08.01: A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma  
  Heather Wakelee, USA
• 11:06 - MA08.02: Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315  
  Frank Griesinger, Germany
• 11:12 - MA08.03: Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3); Plasma ctDNA Analysis  
  Yi Long Wu, China
• 11:18 - MA08.04: Discussant:  
  Baohui Han, China
• 11:30 - MA08.05: Depth of Response to First-Line EGFR TKI Does Not Predict Survival in EGFR-Mutated NSCLC Patients  
  Ting-Hui Wu, Taiwan
• 11:36 - MA08.06: Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy  
  Daniel Morgensztern, USA
11:42 - MA08.07: Prospective Sequential Counts of Total CTC or cKIT+CTC in Advanced NSCLC with 1st Line Chemotherapy (POLICE)  
Yi Long Wu, China

11:48 - MA08.08: Discussant:  
Aaron Mansfield, USA

12:00 - MA08.09: Monitoring Plasma EGFR Mutations during First Line Treatment with EGFR TKIs in NSCLC Patients  
Katja Mohorcic, Slovenia

12:06 - MA08.10: Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR)  
Koichi Azuma, Japan

12:12 - MA08.11: Monitoring the Emergence of EGFR T790M ctDNA in Urine from EGFR Mutated NSCLC Patients to Predict Response to 3rd Generation Anti-EGFR TKIs  
Hatim Husain, USA

12:18 - MA08.12: Discussant:  
Martin Filipits, Austria

12:45 - 14:15: Industry Supported Symposium: ISS Novel Treatment Strategies for ALK+ NSCLC: From Evidence to Practice - Novartis  
Room: Lehar 3-4  
Chair: Solange Peters, Switzerland

12:45 - Welcome & Introduction  
Solange Peters, Switzerland

12:50 - ALK+ NSCLC: not your Typical Patients  
Heather Wakelee, USA

13:05 - Optimizing Outcomes for your ALK+ NSCLC Patients  
Fabrice Barlesi, France

13:20 - The Future of ALK+ NSCLC Treatment and What this Implies for Your Clinical Practice  
Daniel Shao-Weng Tan, Singapore

13:40 - Panel Discussion: Challenges in Sequencing Therapy for your ALK+ NSCLC Patients  
All Faculty

14:10 - Conclusion and Close  
Solange Peters, Switzerland

14:20 - 15:50: Concurrent Abstract Sessions

Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies  
Room: Stolz 1  
Chairs: Raffit Hassan, USA & Paul Baas, The Netherlands

14:20 - OA13.01: A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies  
Paul Baas, Netherlands

14:30 - OA13.02: Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis  
Hedy Kindler, USA
• 14:40 - OA13.03: Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028
  Evan Alley, USA

• 14:50 - OA13.04: Discussant:
  Cornelius Waller, Germany

• 15:05 - OA13.05: Somatic Genetic Alterations and Immune Microenvironment in Malignant Pleural Mesothelioma
  Wickii Vigneswaran, USA

• 15:15 - OA13.06: Autologous Dendritic Cells Loaded with Allogeneic Tumor Cell Lysate (Pheralys®) in Patients with Mesothelioma: Final Results of a Phase I Study
  Joachim Aerts, Netherlands

• 15:25 - OA13.07: Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma
  Tobias Peikert, USA

• 15:35 - OA13.08: Discussant:
  Anna Nowak, Australia

14:20 - 15:40: Mini Oral Session (MA09) Immunotherapy Combinations
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Strauss 2
Chairs: Edward Garon, USA & Martin Sebastian, Germany

• 14:20 - MA09.01: Dual Blockade of PD-1 and C5a/C5aR Synergistically Protects against Non-Small Cell Lung Cancer Tumor Growth
  Ruben Pio, Spain

• 14:26 - MA09.02: Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non-Small Cell Lung Cancer: KEYNOTE-021 Cohort G
  Corey Langer, USA

• 14:32 - MA09.03: Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226
  Rosalyn Juergens, Canada

• 14:38 - MA09.04: Discussant:
  David Planchard, France

• 14:50 - MA09.05: Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial
  Matthew Hellmann, USA

• 14:56 - MA09.06: Viagelpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial
  Daniel Morgensztern, USA

• 14:32 - MA09.07: Phase I Trial of in situ Vaccination with CCL21 Gene-Modified DC Induces Specific Systemic Immune Response and Tumor Infiltrating CD8+ T Cells
  Steven Dubinett, USA

• 15:08 - MA09.08: Discussant:
  Luboš Petruželka, Czech Republic

• 15:20 - MA09.09: First-In-Human Phase I Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)
  Eric Angevin, France

• 15:26 - MA09.10: A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC
  Donald Bergstrom, USA
• 15:32 - MA09.11: Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
  Benjamin Besse, France
• 15:38 - MA09.12: Discussant:
  Clarissa Baldotto, Brazil

Track: Radiology/Staging/Screening
Room: Stolz 2
Chairs: Paris Kosmidis, Greece & Miroslaw Kozlowski, Poland

• 14:20 - MA10.01: Validations of the 8th AJCC/UICC Lung Cancer Staging System in a Large North America Cohort
  Lin Yang, China
• 14:26 - MA10.02: Clinical Staging in the 8th Edition TNM for Lung Cancer is Inaccurate
  Aleksander Mani, UK
  Haval Balata, UK
• 14:38 - MA10.04: Discussant:
  Raymond Osarogiagbon, USA
• 14:50 - MA10.05: Proposals for the Novel Clinical T Categories Based on the Presence of Ground Glass Opacity Component in Lung Adenocarcinoma
  Aritoshi Hattori, Japan
• 14:56 - MA10.06: Centrality Definition in Non Small Cell Lung Cancer. Predictor For Occult Mediastinal Lymph Node Involvement
  David Sanchez-Lorente, Spain
• 14:32 - MA10.07: 18F-Fluorodeoxyglucose Positron Emission Tomography Scan in Solid-Type Stage-I Pulmonary Adenocarcinomas: What Cause False-Negative Cases?
  Tommaso Ricchetti, Italy
• 15:08 - MA10.08: Discussant:
  Amir Onn, Israel
• 15:20 - MA10.09: Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response
  Giovanni Rossi, Italy
• 15:26 - MA10.10: [18F]-FDG-PET/CT Early Response to Nivolumab in NSCLC
  Alexis Cortot, France
• 15:32 - MA10.11: Comparison among Different Radiological Criteria for Assessing Response to Nivolumab in Advanced Non-Small Cell Lung Cancer
  Francesco Grossi, Italy
• 15:38 - MA10.12: Discussant:
  Prasanta R. Mohapatra, India

Track: SCLC/Neuroendocrine Tumors
Room: Strauss 3
Chairs: Primo Lara, USA & Andrea Mohn-Staudner, Austria

• 14:20 - MA11.01: Molecular Profiling of Large Cell Neuroendocrine Carcinoma Using Capture-Based Targeted Sequencing
Zhen Zhou, China
- 14:26 - MA11.02: Mutational Burden in Pulmonary Neuroendocrine Tumors (puNETs)
  Ivana Sullivan, France
- 14:32 - MA11.03: INSM1 is a Novel Biomarker and a Crucial Regulator of the Neuroendocrine Differentiation Pathway in Neuroendocrine Tumours of the Lung
  Fujino Kosuke, Canada
- 14:38 - MA11.04: Discussant:
  Jean Luis Pujol, France
- 14:50 - MA11.05: A Case-Control Study to Test the Use of ctDNA in the Early Detection of SCLC Reveals TP53 Mutations in Non-Cancer Controls
  Lynnette Fernandez-Cuesta, France
- 14:56 - MA11.06: SWOG 0124: Platinum-Sensitivity Status and Post-Progression Survival in Patients with Extensive-Stage Small Cell Lung Cancer
  Primo Lara, USA
- 14:32 - MA11.07: Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial
  Lauren Averett Byers, USA
- 15:08 - MA11.08: Discussant:
  Andrea Ardizzoni, Italy
- 15:20 - MA11.09: Progastrin-Releasing Peptide (ProGRP) to Rule out Progressive Disease in Patients with Small Cell Lung Carcinoma (SCLC)
  Xiaotong Zhang, China
- 15:26 - MA11.10: Prospective Study of Genome-Wide Stressome and Transcriptome Profiling in Patients with Small Cell Lung Cancer Progressing after 1st Line Therapy
  Glen Weiss, USA
- 15:32 - MA11.11: Is Hippocampal Avoidance during Whole Brain Radiotherapy Risky for Small Cell Lung Cancer Patients?
  Esra Kirakli, Turkey
- 15:38 - MA11.12: Discussant:
  Hideo Kunitoh, Japan

14:20 - 15:50: Mini Oral Session (MA12): Miscellaneous Biology/Pathology
Track: Biology/Pathology
Room: Schubert 1
Chairs: Balazs Dome, Austria & William Travis, USA

- 14:20 - MA12.01: Next Generation Sequencing Based Clinical Framework for Analyses of Treatment Predictive Mutations and Gene Fusions in Lung Cancer
  Anna Karlsson, Sweden
- 14:26 - MA12.02: MMP12 and LMO7, Two Key Players on opposite Sides of Early Lung Squamous Cell Carcinoma Development
  Angela Barrett, UK
- 14:32 - MA12.03: Discussant:
  Elisabeth Brambilla, France
- 14:44 - MA12.04: Mitochondrial-Related Proteins, PGAM5 and FUNDC1, in COPD-Associated Non-Small Cell Lung Carcinoma
  Francois Kwong, UK
- 14:50 - MA12.05: Can Tumor Spread through Air Spaces (STAS) in Lung Adenocarcinomas Be Predicted Pre- and Intraoperatively?
  Koji Kameda, USA
• 14:56 - MA12.06: Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis
  Shaohua Lu, USA
• 15:02 - MA12.07: Discussant:
  Erik Thunnissen, The Netherlands
• 15:14 - MA12.08: Clinicopathological Significance of Increasing Percentage of High-Grade Histological Subtypes in Lung Adenocarcinomas
  Shaohua Lu, USA
• 15:20 - MA12.09: Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact
  Takashi Eguchi, USA
• 15:26 - MA12.10: Histological Subtyping of Matched Primary and Metastases Sites in Lung Adenocarcinoma: Significance of Solid Predominance
  Yusuke Takahashi, USA
• 15:32 - MA12.11: Discussant:
  Wendy Cooper, Australia

14:30 - 15:50: Educational Session (ED08): Early-Stage NSCLC: State-of-the-Art Treatment and Perspectives
  Track: Early Stage NSCLC
  Room: Hall C2
  Chairs: Thierry Le Chevalier, France & Masahiro Tsuboi, Japan

  • 14:30 - Surgery of Early-Stage NSCLC
    Michael Rolf Mueller, Austria
  • 14:50 - The Role of Radiotherapy in Early-Stage NSCLC
    Suresh Senan, The Netherlands
  • 15:10 - Adjuvant Chemotherapy of Completely Resected
    Glennwood Goss, Canada
  • 15:30 - Perspectives of Targeted Therapies and Immunotherapy in Completely Resected NSCLC
    Heather Wakelee, USA

14:30 - 15:50: Educational Session (ED09): Advances in Lung Cancer Screening
  Track: Radiology/Staging/Screening
  Room: Hall C8
  Chairs: Christine Berg, USA & Rudolf Huber, Germany

  • 14:30 - Radiological Advances in Lung Cancer Screening
    Mathias Prokop, The Netherlands
  • 14:50 - Risk Prediction Modelling in Lung Cancer Screening Programs
    Martin Tammemägi, Canada
  • 15:10 - Overdiagnosis in Lung Cancer Screening
    Charles Powell, USA
  • 15:30 - Cost Effectiveness of CT Screening
    Bruce Pyenson, USA

14:30 - 15:50: Science Session (SC16): Superior Sulcus Tumors
  Track: Locally Advanced NSCLC | Early Stage NSCLC | Radiology/Staging/Screening
  Room: Lehár 1-2
  Chairs: David Jones, USA & Walter Klepetko, Austria
• 14:30 - Imaging Techniques for Staging and Restaging of Superior Sulcus Tumors
  Helmut Prosch, Austria
• 14:50 - Surgical Approaches in Superior Sulcus Tumors
  Dominique Grunenwald, France
• 15:10 - Radiotherapy for Sulcus Superior Tumors
  Maria Werner-Wasik, USA
• 15:30 - Individualized Extended Lung Cancer Surgery: The Chinese Experience
  Qinghua Zhou, China

Track: Regional Aspects/Health Policy/Public Health
Room: Strauss 1
Chairs: Carlos Vallejos, Peru & Paul Bunn, Jr., USA

• 14:25 - Lung Cancer in Russia: Challenges and Perspectives
  Vera Gorbunova, Russia
• 14:40 - Lung Cancer in China: Challenges and Perspectives
  Li Zhang, China
• 14:55 - Lung Cancer in India: Challenges and Perspectives
  Digambar Behera, India
• 15:10 - Lung Cancer in Latin America: Challenges and Perspectives
  Eduardo Richardet, Argentina
• 15:25 - Lung Cancer in Africa: Challenges and Perspectives
  Rabab Gaafar, Egypt
• 15:40 - Lung Cancer in Low and Middle Income Countries: A Comprehensive Cancer Control Approach
  Nelly Enwerem-Bromson, IAEA/PACT, Austria

14:30 - 15:45: Pro-Con Session (PC02): By 2030 Chemotherapy will Remain Standard of Care for the Majority of Patients with NSCLC Stages I-IV
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C7
Chairs: Enriqueta Felip, Spain & Georg Pall, Germany

• 14:30 - Introduction & Vote
  Georg Pall, Germany
• 14:45 - Pro Chemotherapy
  Nasser Hanna, USA
• 15:05 - Contra Chemotherapy
  Karen Kelly, USA
• 15:25 - Discussion & Vote
  Enriqueta Felip, Spain

14:30 - 15:45: Nurses Session (NU04): Managing Toxicity
Track: Nurses
Room: Schubert 5
Chairs: Mary Hesdorffer, USA & Marianne Davies, USA
14:30 - Management of Toxicities Associated with Immunotherapy in the Lung Cancer Patients
Michelle Turner, USA

14:50 - Experience of Lung Cancer Patients Receiving Immunotherapy
Rachel Thomas, UK

15:10 - Where are we With TKI Toxicities
Beth Eaby-Sandy, USA

15:30 - Q&A

14:30 - 15:45: Patient Advocacy Session (PA04): FOCUS ON ADVOCACY AND COMMUNICATION: Joint IASLC/Global Lung Cancer Coalition Session (GLCC)
Track: Patient Support and Advocacy Groups
Room: Schubert 6
Chairs: Aoife McNamara, Ireland & Andreja Šajnić, Croatia

14:30 - A Realistic Goal? Achieving a Tobacco Free Ireland by 2025
Donal Buggy, Ireland

14:45 - The Global State of Lung Cancer Research - Communicating the Messages
Sarah Winstone, UK

15:05 - Helpline: Adapting to Changing Needs and Evolving Science
Jennifer King, USA

15:25 - How it Feels Campaign: The Impact of a Large General Public Campaign
Kay Bayne, USA

14:30 - 15:00: IASLC Business Meeting
Room: Schubert 2

14:30 - 15:45: Poster Session with Presenters Present (P2)
Room: Hall B (Poster Area)

Click here for the 17th IASLC WCLC Poster Program >>

16:00 - 17:30: Educational Session (ED10): Locally Advanced NSCLC: State-of-the-Art Treatment
Track: Locally Advanced NSCLC
Room: Hall C1
Chairs: Wilfried Eberhardt, Germany & Kenji Suzuki, Japan

16:00 - Chemoradiotherapy of Stage III NSCLC
Francoise Mornex, France

16:25 - The Role of Surgery in Stage III NSCLC
Walter Klepetko, Austria

16:45 - New Developments in Radiotherapy of Stage III NSCLC
Jacek Jassem, Poland

17:05 - New Developments for Systemic Therapies in Stage III NSCLC
Everett Vokes, USA

17:25 - Q&A

16:00 - 17:30: Science Session (SC18): Precision Screening for Lung Cancer
Room: Lehar 1-2
Track: Radiology/Staging/Screening
Chairs: Andrew Nicholson, UK & Gyula Ostoros, Hungary
16:00 - 17:00: Field Cancerization in the Airways and its Application to Lung Cancer Early Detection
Ignacio Wistuba, USA

16:20 - Integrating Lung Cancer Biomarkers into Future Screening Programs
Pierre Massion, USA

16:40 - Lung Cancer Screening, COPD and Cardiovascular Diseases
Rudolf Huber, Germany

17:00 - Exhaled Biomarker Fingerprints for Early Detection
Ildiko Horvath, Hungary

17:15 - UK Lung Screening Trial Cost Effectiveness and Current Planning Status of International Lung Cancer Screening Programs
John Field, UK

16:00 - 17:30: Science Session (SC19): Interventional Pulmonology in Diagnosis and Treatment of Thoracic Malignancies
Track: Pulmonology | Surgery
Room: Lehar 3-4
Chairs: Yoichi Nakanishi, Japan & Ruxandra Ulmeanu, Romania

• 16:00 - Diagnosis of Lung Cancer: Multimodal Devices for Peripheral Pulmonary Lesions
  Noriaki Kurimoto, Japan
• 16:20 - Invasive Staging of Lung Cancer: EBUS, EUS and Beyond
  Kazuhiro Yasufuku, Canada
• 16:40 - Medical Thoracoscopy
  Ales Rozman, Slovenia
• 17:00 - 17:20: Endobronchial Palliation in Thoracic Malignancies
  Zsolt Pápai-Székely, Hungary

16:00 - 17:30: Science Session (SC20): Small is Beautiful: Impact of Surgical Approach
Track: Surgery
Room: Strauss 1
Chairs: Alan Sihoe, Hong Kong & Alper Toker, Turkey

• 16:00 - Muscle-Sparing Thoracotomy: Can it Still be Considered a Standard?
  Clemens Aigner, Germany
• 16:20 - What Have we Achieved? Should it be Performed for Stages Higher than Stage I Disease?
  Tomasz Grodzki, Poland
• 16:40 - Robotic Surgery: What can be Done?
  Franca Melfi, Italy
• 17:00 - Uniportal VATS
  Diego Gonzalez Rivas, Spain
• 17:20 - Q&A

16:00 - 17:30: Science Session (SC21): Predictive Biomarkers for Outcome of Systemic Therapy in NSCLC
Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C7
Chairs: Keith Kerr, UK & Tetsuya Mitsudomi, Japan
• 16:00 - Predictive Biomarkers in NSCLC: The Impact of Tumor Heterogeneity
  Yasushi Yatabe, Japan
• 16:20 - Predictive Biomarkers for Chemotherapy of NSCLC
  Martin Filipits, Austria
• 16:40 - Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer
  Fred Hirsch, USA
• 17:00 - Patient-Derived Xenografts for Guiding Therapy of Lung Cancer
  Byoung Chul Cho, South Korea
• 17:15 - Emerging Role of Liquid Biopsies in NSCLC
  Philipp Mack, USA

16:00 - 17:30: Science Session (SC22): Selection and Monitoring of Patients for Immune Checkpoint Inhibitors
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C8
Chairs: Giorgio Scagliotti, Italy & Johan Vansteenkiste, Belgium

• 16:00 - How do I Define Optimal Candidates for Immunotherapy in my Practice?
  Johan Vansteenkiste, Belgium
• 16:20 - How do I Monitor for Efficacy?
  Naiyer Rizvi, USA
• 16:40 - How do I Monitor for and Treat Immune-Related Events?
  Alexander Spira, USA
• 17:00 - How can Immunotherapy be Implemented in a Cost-Effective Strategy?
  Christoph Zielinski, Austria
• 17:20 - Q&A

16:00 - 17:30: Science Session (SC23): The Importance of Co-Operative Groups
Track: Scientific Co-Operation/Research Groups
Room: Strauss 3
Chairs: Jaime de la Garza, Mexico & Jin Soo Lee, South Korea

• 16:00 - Cooperative Groups in Latin America
  Clarissa Mathias, Brazil
• 16:15 - Co-Operative Groups in Europe: Lessons Learned and Perspectives
  Solange Peters, Switzerland
• 16:30 - How Could High-Volume Centers in Developing Countries Access Cooperative Group Trials?
  Ufuk Yilmaz, Turkey
• 16:45 - Cooperative Groups in China: The CSCO Experience
  Qing Zhou, China
• 17:00 - Co-Operative Groups in North America
  Shakun Malik, USA
• 17:15 - Challenges and Costs of Cooperative Group Trials
  Thomas Brodowicz, Austria

16:00 - 17:30: Interactive Session (IA07): Target Delineation* (Ticketed Session: €35,00)
Track: Radiotherapy
Room: Schubert 3
Coordinators: Karin Dieckmann, Austria & Helmut Prosch, Austria
Group II (Space is limited to 20 participants)
Trainers: Corinne Faivre-Finn, UK, Laurie Gaspar, USA & Billy Loo, USA
*Please note that this session is a duplicate of the session on Monday

16:00 - 17:30: Interactive Session (IA08): Tobacco & Youth
Track: Epidemiology/Tobacco Control and Cessation/Prevention
Room: Hall C2
Chairs: Corneli Radu-Loghin, Romania & TBD

- Tobacco Use in Low-Income Countries
  Nise Yamaguchi, Brazil
- Tobacco use in Austrian Young People
  Daniela Jahn-Kuch, Austria
- How Technology can Assist in Lung Cancer Prevention
  Alexander Prokhorov, USA
- Tobacco Control Policies and Youth Smoking
  Florin Mihaltan, Romania

16:00 - 17:30: Concurrent Abstract Sessions

16:00 - 17:30: Oral Session (OA14): Nurses in Care for Lung Cancer and in Research
Track: Nurses
Room: Schubert 5
Chairs: Melissa Culligan, USA & Massey Nematollahi, Canada

- 16:00 - OA14.01: Acceptability of an Advanced Practice Nurse in Lung Cancer by Health Professionals and Patients: A Qualitative Exploration
  Andrea Serena, Switzerland
- 16:10 - OA14.02: Nursing and Allied Healthcare Practitioner Driven Initiative to Develop an Integrated Educational and Assessment Program for Immunotherapy
  Marianne Davies, USA
- 16:20 - OA14.03: Integrating Therapies into a Specialist Lung Cancer Nursing Team: An Evaluation
  Carol Brimacombe, UK
- 16:10 - OA14.04: Discussant:
  Beth Eaby-Sandy, USA
- 16:45 - OA14.05: A Framework to Support the Lung Cancer Nurse Specialist in the Development and Evaluation of Nurse-Led Clinics
  Sharon Savory, UK
- 16:55 - OA14.06: The Role of a Multi-Disciplinary Team Approach to Early Rehabilitation and Symptom Management in Thoracic Oncology
  Pippa Labuc, UK
- 17:05 - OA14.07: The Relationship between Lung Cancer Stigma and Patient Reported Outcomes
  Liane Lewis, UK
- 17:15 - OA14.08: Discussant:
  Mary Duffy, Australia

16:00 - 17:30: Oral Session (OA15): Sublobar Resections for Early Stage NSCLC
Track: Surgery
Room: Stolz 2
Chairs: Mir Hoda, Austria & David Waller, United Kingdom

- 16:00 - OA15.01: Limited Resection Trial for Pulmonary Sub-solid Nodules: Case Selection Based on High Resolution CT: Outcome at Median Follow-up of 105 Months
  Junji Yoshida, Japan
- 16:10 - OA15.02: Survival Outcomes in Sublobar Resection for Clinical T1N0M0 Non-Small Cell Lung Cancer: Wedge Resection or Segmentectomy
  Aki Kobayashi, Japan
- 16:20 - OA15.03: Comparison of Prognosis between Lobectomy and Sublobar Resection for Clinical Stage I Non-Small Cell Lung Cancer with Interstitial Lung Disease
  Yasuhiro Tsutani, Japan
- 16:30 - OA15.04: Discussant:
  Stefan Watzka, Austria
- 16:45 - OA15.05: Anatomical Pulmonary Segmentectomy and Sub-Segmentectomy for Lung Cancer Using the Novel Fluorescence Technique with Vitamin B2
  Ryuichi Waseda, Japan
- 16:55 - OA15.06: The Efficacy of Lung Volume Analyzer for Measuring Resection Margin in Pulmonary Segmentectomy for Malignant Diseases
  Yasuo Sekine, Japan
- 17:05 - OA15.07: Is Necessary Completion Lobectomy in NSCLC (≤ 2cm) with Visceral Pleural Invasion or Lymphovascular Invasion after Sublobar Resection?
  Youngkyu Moon, South Korea
- 17:15 - OA15.08: Discussant:
  Wen-Zhao Zhong, China

16:00 - 17:30: Oral Session (OA16): Improving the Quality of Lung Cancer Care - Patients Perspective
Track: Patient Support and Advocacy Groups
Room: Schubert 6
Chairs: Gudrun Kreye, Austria & Daniel Shao-Weng, Tan, Singapore

- 16:00 - OA16.01: The Role of Patient Groups in Integrating the Patient Voice into Drug Funding Decisions
  Christina Sit, Canada
- 16:10 - OA16.02: Shared Decision Making (SDM) and Patient Decision Aids (PDAs) in Lung Cancer: Survey of Patients, Significant Others or Caregivers
  Laurie Gaspar, USA
- 16:20 - OA16.03: The ALCF Centers of Excellence Model Delivers a Standard of Care to the Community Similar to Academic and Research Centers
  Raymond Osarogiagbon, USA
- 16:30 - OA16.04: Discussant:
  Joan Schiller, USA
- 16:45 - OA16.05: Socioeconomic Determinants of Late Diagnosis of Lung Cancer in France: A Nationwide Study (the TERRITOIRE Study)
  Pierre Jean Souquet, France
- 16:55 - OA16.06: Willingness for Multiple Biopsies to Improve Quality of Lung Cancer Care: Understanding the Patient Perspective
  Upal Basu Roy, USA
- 17:05 - OA16.07: Patient-Driven Epidemiologic Assessment of ROS1-Fusion Driven Cancers
  Guneet Walia, USA
- 17:15 - OA16.08: Discussant:
16:00 - 17:30: Oral Session (OA17): Aspects of Health Policies and Public Health
Track: Regional Aspects/Health Policy/Public Health
Room: Schubert 1
Chairs: Meinhard Kneussl, Austria & TBD

- 16:00 - OA17.01: Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
  Gilberto Lopes, Brazil
- 16:10 - OA17.02: Potential Health and Economic Consequences of Organized vs Opportunistic Lung Cancer Screening in Canada
  William Evans, Canada
- 16:20 - OA17.03: Insurance Type Influences Stage, Treatment, and Survival in Asian American Lung Cancer Patients
  Apichat Tantraworasin, USA
- 16:30 - OA17.04: Discussant:
  Digambar Behera, India
- 16:45 - OA17.05: Survival in a Cohort of Patients with Lung Cancer: The Role of Age and Gender on Prognosis
  Juliana Franceschini, Brazil
- 16:55 - OA17.06: Make the World Beautiful and Healthy by Making Your Country Smoke Free: Case Study between Iceland and Thailand?
  May Cho, Thailand
- 17:05 - OA17.07: Time from the Identification of a Suspicious Pulmonary Lesion to the Treatment of Non-Small Cell Lung Cancer
  Claire Hiles, USA
- 17:15 - OA17.08: Discussant:
  Govind Babu, India

16:00 - 17:30: Mini Oral Session (MA13): Modern Technologies and Biological Factors in Radiotherapy
Track: Radiotherapy
Room: Stolz 1
Chairs: Michael Thomas, Germany & Paul Mitchell, Australia

- 16:00 - MA13.01: Markerless Tumour Tracking during Lung Radiotherapy Using Intrafraction X-Ray Imaging
  Chun-Chien (Andy) Shieh, Australia
- 16:06 - MA13.02: First-In-Human Clinical Experience with Real-Time Tumor Tracking via MLC Tracking for Stereotactic Radiotherapy of Lung Cancer
  Jeremy Booth, Australia
- 16:12 - MA13.03: Analysis of Intra-Thoracic Anatomical Changes Observed in Clinical Workflow of Cone-Beam CT Guided Radiotherapy for Lung Cancer
  Josè Belderbos, Netherlands
- 16:18 - MA13.04: Discussant:
  Christoph Pöttgen, Germany
- 16:30 - MA13.05: Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data
  Elizabeth Dudnik, Israel
- 16:36 - MA13.06: Integrative Genomic Profiling Identifies BRAF Mutations as Novel Radiotherapeutic Targets in Adenocarcinomas of the Lung
Mohamed Abazeed, USA

16:42 - MA13.07: Tumor-Targeted Radiation Promotes Abscopal Efficacy of Regionally Administered CAR T Cells: A Rationale for Clinical Trial
Masha Zeltsman, USA

16:48 - MA13.08: Discussant:
Miklos Pless, Switzerland

17:00 - MA13.09: Serial FDG and FLT PET/CT during Curative-Intent Chemo-Radiotherapy for NSCLC Impacts Patient Management and May Predict Clinical Outcomes
David Ball, Australia

Shyama Tetar, Netherlands

17:12 - MA13.11: Investigating the Feasibility of Establishing a Prospective Cohort of Lung Cancer Patients Following Radiotherapy with Curative Intent
Lynn Calman, UK

17:18 - MA13.12: Discussant:
Antonio Juretic, Croatia

16:00 - 17:30: Mini Oral Session (MA14): Immunotherapy in Advanced NSCLC: Biomarkers and Costs
Track: Advanced NSCLC
Room: Strauss 2
Chairs: Martin Reck, Germany & David Spigel, USA

16:00 - MA14.01: Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)
Siraj Ali, USA

16:06 - MA14.02: Evaluation of PD1/PDL1 Expression on Peripheral Blood Cells Subpopulations in Patients with Non-Small Cell Lung Cancer
Oscar Arrieta, Mexico

16:12 - MA14.03: The Impact of Genomic Landscape of EGFR Mutant NSCLC on Response to Targeted and Immune Therapy
Yasir Elamin, USA

16:18 - MA14.04: Discussant:
Marcin Moniuszko, Poland

16:30 - MA14.05: Implications of Implementation of a PD-L1 Biomarker-Based Strategy for Treatment of Advanced NSCLC
Thomas Burke, USA

16:36 - MA14.06: Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)
Giuseppe Lo Russo, Italy

16:42 - MA14.07: Real Life Experience with Immunotherapy in the Netherlands
Robert Schouten, Netherlands

16:48 - MA14.08: Discussant:
Luis Raez, USA

17:00 - MA14.09: Demonstrating Life Expectancy Gains with Immuno-Oncology (IO) Therapies
Robert Figlin, USA

17:06 - MA14.10: Relative Impact of Disease Management Costs in the Economics of Pembrolizumab in Previously Treated PD-L1 Positive Advanced NSCLC
Thomas Burke, USA
17:12 - MA14.11: An Estimate of the Economic Impact of Immunotherapy Relative to PD-L1 Expression in Brazil - An Update with Brazilian Costs
   Gilberto Lopes, Brazil
17:18 - MA14.12: Discussant:
   George Simon, USA

17:45 - 19:15: Industry Supported Symposium: ISS Harnessing the Power of Immunotherapy and Targeted Therapy: Translating Evidence into Practice - Roche
Room: Hall C2
Chairs: David Spigel, USA

- 17:45 - Welcome & Introduction
  David Spigel, USA
- 17:50 - ALK: The Power of Targeted Therapy
  Frank Griesinger, Germany
- 18:15 - Latest Developments in the Treatment of EGFR Mut+ NSCLC
  Federico Cappuzzo, Italy
- 18:30 - The Power of the Immune System: Immunotherapy in Practice
  Achim Rittmeyer, Germany
- 19:10 - Summary and Close
  David Spigel, USA
Wednesday, December 7, 2016

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH05)
Tracks: Advanced NSCLC
    Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C1
Chairs: Jana Skříčková, Czech Republic & Miroslav Samarzija, Croatia

- Chemotherapy of Advanced NSCLC:
  Chandra Belani, USA
- Targeted Therapy of Advanced NSCLC:
  James Spicer, UK
- Immunotherapy of Advanced NSCLC:
  Lucio Crino, Italy

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH06)
Tracks: Radiotherapy
    Palliative Care/Ethics
    Regional Aspects/Health Policy/Public Health
Room: Hall C7
Chairs: Peter Berzinec, Slovakia & Herbert Watzke, Austria

- Radiotherapy:
  Christoph Pöttgen, Germany
- Palliative Care/Ethics:
  Corey Langer, USA
- Regional Aspects/Education:
  Prasanta R. Mohapatra, India

07:30 - 08:30: Special Workshop (WS09): Tobacco Free Portfolios
- Learn How to Change the World for the Better - One Pension Fund at a Time!
  Bronwyn King, Australia
Room: Strauss 2

Overview: This workshop will provide a practical overview regarding how to effectively advocate for tobacco-free investment within your own country.

Who should attend?
- Leaders of international cancer agencies/organisations
- Any interested parties who might consider supporting a Tobacco Free Portfolios Regional Director or allocating this task to a staff member within the organization
- Motivated individuals who would like to contribute to the work

What will you learn? The Tobacco Free Portfolios team will cover:
- The case for tobacco-free investment: prospective investment risks including regulatory changes, litigation, human rights abuses and why tobacco as a unique consideration.
- Engaging the finance sector by understanding their priorities and concerns and learning to speak their language.
- Overview of financial investment in tobacco: from indices to collective investment vehicles.
• Becoming confident in answering the common questions posed by investors, finance leaders and government officials.

07:30 - 08:30: Meet the Expert (MTE21) (Ticketed Session: €35,00)
Track: Biology/Pathology
Room: Schubert 1
• Next Generation Sequencing
  Ignacio Wistuba, USA & Xuefei Li, China

07:30 - 08:30: Meet the Expert (MTE22) (Ticketed Session: €35,00)
Track: Radiology/Staging/Screening
Room: Schubert 2
• Perspectives in Lung Cancer Imaging
  Thomas Henzler, Germany & Georgios Karanikas, Austria

07:30 - 08:30: Meet the Expert (MTE23) (Ticketed Session: €35,00)
Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy
Room: Schubert 3
• Biomarker Characterization: Challenges and Perspectives
  Rafael Rosell, Spain & Leonhard Müllauer, Austria

07:30 - 08:30: Meet the Expert (MTE24) (Ticketed Session: €35,00)
Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy
Room: Schubert 4
• Immunohistochemical Assessment of Biomarkers for Immune Checkpoint Inhibitors
  Vera Capelozi, Brazil

07:30 - 08:30: Meet the Expert (MTE25) (Ticketed Session: €35,00)
Track: SCLC/Neuroendocrine Tumors | Radiotherapy
Room: Schubert 5
• Radiotherapy in Small Cell Lung Cancer
  Cecile Le Pechoux, France & Andrew Turrisi, USA

07:30 - 08:30: Meet the Expert (MTE26) (Ticketed Session: €35,00)
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Schubert 6
• EGFR Targeted Therapies: Lessons Learned
  Shun Lu, China & Frederico Cappuzzo, Italy

07:30 - 08:30: Meet the Expert (MTE27) (Ticketed Session: €35,00)
Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Lehár 1-2
• Treatment of Lung Cancer Patients with Poor Performance Status
  Rogerio Lilienbaum, USA & Luboš Petruželka, Czech Republic

07:30 - 08:30: Meet the Expert (MTE28) (Ticketed Session: €35,00)
Track: Regional Aspects/Health Policy/Public Health | Chemotherapy/Targeted Therapy/Immunotherapy
Room: Lehár 3-4
• Implementation of Precision Medicine in Routine Practice: The Latin American Experience
  Marileila Varella-Garcia, USA & Mercedes Liliana Dalurzo, Argentina
07:30 - 08:30: Meet the Expert (MTE29) (Ticketed Session: €35,00)
Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
Room: Stolz 1
- Advances in Malignant Pleural Mesothelioma
  Paolo Boffetta, USA & Nico van Zandwijk, Australia

07:30 - 08:30: Meet the Expert (MTE30) (Ticketed Session: €35,00)
Track: Surgery
Room: Stolz 2
- Non-intubated Thoracic Surgery
  Teodor Horvath, Czech Republic, Jin-Shing Chen, Taiwan & Ya-Jung Cheng, Taiwan.

08:35 - 09:40: Plenary Session (PL04a): Immune Checkpoint Inhibitors in Advanced NSCLC
Room: Hall D (Plenary Hall)
Chairs: Jean-Charles Soria, France & Caicun Zhou, China

  - 08:45 - PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024
    Julie Brahmer, USA
  - 08:55 - PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses
    Shirish Gadgeel, USA
  - 09:05 - PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study
    Marina Garassino, Italy
  - 09:15 - PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC
    Julien Adam, France
  - 09:25 - PL04a.05: Discussant:
    Michael Boyer, Australia

09:45 - 10:15: Plenary Keynote Lecture (PL04b)
Chairs: Fred Hirsch, USA & Robert Pirker, Austria

  - 09:45 - PL04b.01: The Role of Doctors in a Globalized World
    Alfred Gusenbauer, Former Federal Chancellor of the Republic of Austria

10:25 - 10:55: Exhibit Showcase Session: Otsuka Pharmaceutical
Room: Hall B (Exhibit Showcase Theater)

Relevance and management of hyponatremia in lung cancer - current perspectives

Hyponatremia is the most frequent electrolyte and body fluid balance disturbance encountered in hospital clinical practice. It is considered an unfavorable prognostic factor in patients with cancer and differential diagnosis is challenging.

The objective of the “Exhibit Showcase Session” by Prim. Assoc. Prof. Doz.Dr. Marcus Säemann, Wilhelmminenspital Wien, Austria is to discuss current challenges in the diagnosis and treatment of patients with hyponatremia, with emphasis on aspects of cancer patients

10:20 - 11:00: Poster Session
Room: Hall B (Poster Area)

10:30 - 11:45: Press Conference (PR04): Advanced Care
Room: Schubert 1
Chairs: Michael Boyer, Chris O’Brien Lifehouse, Australia

- **PR04.01:** Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024 - Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
- **PR04.02:** OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses - Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA
- **PR04.03:** Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study - Marina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
- **PR04.04:** Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC - Julien Adam, Gustave Roussy Cancer Campus, France
- **PR04.05:** A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): With Translational Research (TR) Biopies - Paul Baas, Netherlands Cancer Institute, Netherlands

11:00 - 12:30: Educational Session (ED11): Advanced NSCLC: State-of-the-Art Treatment
Track: Advanced NSCLC | Chemotherapy/Targeted Therapy/Immunotherapy
Room: Hall C8
Chairs: Christian Manegold, Germany & Caicun Zhou, China

- **11:00 - Systemic Therapy for Advanced Oncogene-Driven NSCLC**
  David Gandara, USA
- **11:25 - Systemic Therapy for Advanced Non-Oncogene-Driven NSCLC**
  Giorgio Scagliotti, Italy
- **11:50 - Management of Oligo-Metastatic NSCLC**
  Jaroslaw Kuzdzal, Poland
- **12:10 - Palliative Radiotherapy of Advanced NSCLC**
  Karin Dieckmann, Austria

11:00 - 12:30: Educational Session (ED12): Regional Tobacco Control Policies: Advances & Challenges
Track: Epidemiology/Tobacco Control and Cessation/Prevention
Room: Hall C7
Chairs: Zarihah Zain, Malaysia & Florin Mihaltan, Romania

- **11:00 - Tobacco Control Policies in Eastern Europe**
  Gábor Kovács, Hungary
- **11:15 - Tobacco Control: The Turkish Experience**
  Nazmi Bilir, Turkey
- **11:30 - Tobacco Control: The Indian Experience**
  Surendra Shastri, India
- **11:45 - Tobacco Control Policies in China**
  Xiuyi Zhi, China
- **12:00 - Tobacco Control Policies in Japan**
  Tomotaka Sobue, Japan
- **12:15 - Tobacco Control Policies in Latin America**
Nise Yamaguchi, Brazil

11:00 - 12:30: Educational Session (ED13): Treatment of Malignant Pleural Mesothelioma
Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
Room: Hall C1
Chairs: Hedy Kindler, USA & Nico van Zandwijk, Australia

- 11:00 - Biomarkers in Malignant Pleural Mesothelioma
  Harvey Pass, USA
- 11:15 - Tissue-Based Biomarkers
  Glen Reid, Australia
- 11:30 - Surgery with Adjuvant or Induction Radiotherapy
  Marc de Perrot, Canada
- 11:45 - Systemic Induction Therapy of Malignant Pleural Mesothelioma
  Paul Baas, The Netherlands
- 12:00 - Systemic Therapy of Inoperable Malignant Pleural Mesothelioma
  Arnaud Scherpereel, France
- 12:15 - Mesothelioma in a Setting of Germline BAP1 Mutations
  Michele Carbone, USA

11:00 - 12:30: Science Session (SC24): Management of Indeterminate Pulmonary Nodules
Track: Pulmonology
Room: Hall C2
Chairs: Nevena Seken, Serbia & Oleg Pikin, Russia

- 11:00 - Risk Assessment in the Management of Pulmonary Nodules
  Satoshi Shiono, Japan
- 11:20 - Radiological Techniques for the Evaluation of Pulmonary Nodules
  Reginald Munden, USA
- 11:35 - The Role of the Pulmonologist in the Management of Pulmonary Nodules
  Philippe Lambin, The Netherlands
- 11:50 - The Role of the Pathologist in the Management of Indeterminate Pulmonary Nodules
  Keith Kerr, UK
- 12:10 - Indication and Techniques of Surgery
  Ugo Pastorino, Italy

11:00 - 12:30: Science Session (SC25): The Role of Surgeons in Multimodality Clinical Trials
Track: Surgery
Room: Strauss 2
Chairs: Norihiko Ikeda, Japan & Georgios Stamatis, Germany

- 11:00 - Trial Design for Multimodality Treatment of NSCLC
  David Jones, USA
- 11:20 - Quality of Resection in Induction and Adjuvant Clinical Trials
  Eric Vallieres, USA
- 11:40 - Quality of Centers and Patient Inclusion
  John Edwards, UK
- 12:00 - The Importance of Cooperation: The Essen Experience
  Wilfried Eberhardt, Germany
- 12:20 - Multimodality Trials: The Chinese Experience
  Ke-Neng Chen, China
11:00 - 12:30: Science Session (SC26): Angiogenesis Inhibition: Advances & Perspectives  
Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy  
Room: Lehar 3-4  
Chairs: Takashi Seto, Japan & Ross Soo, Singapore

- 11:00 - Biology of Angiogenesis  
  John Heymach, USA  
- 11:20 - Angiogenesis Inhibition in Lung Cancer: Recent Advances and Perspectives  
  Michael Boyer, Australia  
- 11:40 - Predictive Biomarkers for Angiogenesis Inhibitors: An Update  
  Martin Reck, Germany  
- 12:00 - Novel Imaging Technique  
  Stefan Schönberg, Germany  
- 12:20 - Q&A

11:00 - 12:30: Science Session (SC27): P53 and KRAS Mutations in NSCLC  
Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy  
Room: Strauss 3  
Chairs: Filippo de Marinis, Italy & Hideo Kunitoh, Japan

- 11:00 - The Role of p53 in Lung Cancer  
  Pierre Hainaut, France  
- 11:20 - Biology of KRAS Mutations  
  József Timár, Hungary  
- 11:40 - Transforming KRAS into a Clinically Relevant Biomarker  
  Kenneth O’Byrne, Australia  
- 12:00 - KRAS-Directed Drug Therapy in Advanced NSCLC  
  Pasi Jänne, USA  
- 12:20 - Q&A

11:00 - 12:30: Science Session (SC28): Novel Clinical Trial Designs  
Track: Trial Design/Statistics  
Room: Lehar 1-2  
Chairs: Stefan Michiels, France & Lothar Pilz, Germany

- 11:00 - Phase I Trials of Targeted Therapies  
  Alex Adjei, USA  
- 11:20 - Umbrella and Basket Designs  
  Daniel Shao-Weng Tan, Singapore  
- 11:40 - Biomarker “Test and Validation” Designs  
  Mary Redman, USA  
- 12:00 - Adaptive Clinical Trial Designs  
  Vassiliki Papadimitrakopoulou, USA  
- 12:20 - Q&A

11:00 - 12:30: Science Session (SC29): Access, Value Assessments and Affordability of Novel Therapies  
Track: Chemotherapy/Targeted Therapy/Immunotherapy | Patient Support and Advocacy Groups  
Room: Strauss 1  
Chairs: Maciej Krzakowski, Poland & Eduardo Richardet, Argentina
• 11:00 - Affordability of Novel Therapies: A Global Challenge
  Richard Sullivan, UK
• 11:20 - Value-Based Assessments in Lung Cancer Therapy: The North American Perspective
  Ronan Kelly, USA
• 11:40 - Value-based Assessments in Lung Cancer Therapy: The ESMO Perspective
  Nathan Cherny, Israel
• 12:00 - Solutions for Low-Income Countries
  Gilberto Lopes, Brazil
• 12:15 - The Thai Experience to overcome High Cost Drug in Cancer
  Sumitra Thongprasert, Thailand

11:00 - 12:30: Concurrent Abstract Sessions

11:00 - 12:30: Oral Session (OA18): New Insights in the Treatment of Thymic Malignancies
Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
Room: Schubert 2
Chairs: Nicolas Girard, France & Stefan Watzka, Austria

• 11:00 - OA18.01: Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
  Clémence Basse, France
• 11:10 - OA18.02: Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma
  Arun Rajan, USA
• 11:20 - OA18.03: Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)
  Arun Rajan, USA
• 11:30 - OA18.04: Discussant:
  Andreas Rimner, USA
• 11:45 - OA18.05: FDG-PET in Thymic Epithelial Tumors: An Evaluation of Only Resected Tumors
  Kazuo Nakagawa, Japan
• 11:55 - OA18.06: Treatment, Outcome and Prognostic Factors of Patients with Thymic Epithelial Tumors at First Recurrence
  Rohit Lal, UK
• 12:05 - OA18.07: Quality of Resection and Outcome in Stage III TETs: The French RYTHMIC Network Experience
  Nicolas Girard, France
• 12:15 - OA18.08: Discussant:
  Enrico Ruffini, Italy

11:00 - 12:30: Oral Session (OA19): Translational Research in Early Stage NSCLC
Track: Early Stage NSCLC
Room: Schubert 3
Chairs: Gerwin Heller, Austria & Glenwood Goss, Canada

• 11:00 - OA19.01: A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium
  Raphael Bueno, USA
• 11:10 - OA19.02: Sex Differences Are Detected in the Profile of Tumor Associated Inflammatory Cells (TAICs) Are Lung Adenocarcinoma
  Carmen Behrens, USA
• 11:20 - OA19.03: Identify Lung Adenocarcinoma in Situ among Pulmonary Micro-Nodules through Blood Gene Expression Profiles
  Baohui Han, China
• 11:30 - OA19.04: Discussant:
  Charles Rudin, USA
• 11:45 - OA19.05: High Oncofetal Chondroitin Sulfate Expression is an Independent Prognostic Factor of Poor Survival in Early-Stage NSCLC
  Zoltan Lohinai, Hungary
• 11:55 - OA19.06: Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer
  Gavitt Woodard, USA
• 12:05 - OA19.07: Difference of Postoperative Survival Due to the Type of EGFR Gene Mutation in Surgically Resected Lung Adenocarcinomas
  Kazuki Hayasaka, Japan
• 12:15 - OA19.08: Discussant:
  Ken Andre Olaussen, France

11:00 - 12:30: Oral Session (OA20): Immunotherapy and Markers
Track: Biology/Pathology
Room: Stolz 2
Chairs: Martin Früh, Switzerland & Clarissa Baldotto, Brazil

• 11:00 - OA20.01: Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
  Marcin Kowanetz, USA
• 11:10 - OA20.02: Neoantigen Targeting in NSCLC Patients with Complete Response to Anti-PD-1 Immunotherapy
  Kellie Smith, USA
• 11:20 - OA20.03: Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy
  Zachary Tano, USA
• 11:30 - OA20.04: Discussant:
  Wolfgang Hilbe, Austria
• 11:45 - OA20.05: The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non-Small Cell Lung Carcinomas
  Jaime Rodriguez-Canales, USA
• 11:55 - OA20.06: Prospective ImmunogenomicPrOfiling of Non-Small Cell Lung Cancer - The ICON Project
  Boris Sepesi, USA
• 12:05 - OA20.07: HHLA2, a New Immune Checkpoint Member of the B7 Family, is Widely Expressed in Human Lung Cancer and Associated with Mutational Status
  Haiying Cheng, USA
• 12:15 - OA20.08: Discussant:
  Helmut Popper, Austria

11:00 - 12:30: Oral Session (OA21): Palliative and Supportive Care for Lung Cancer Patients
Track: Palliative Care/Ethics
Room: Schubert 5
Chairs: Carlos Silva, Argentina & Herbert Watzke, Austria

- 11:00 - OA21.01: Pooled Analysis of the Incidence and Risk of Treatment-Related Pneumonitis with Anti-PD-1/PD-L1 Therapies in Cancer Patients
  Shaodong Hong, China
- 11:10 - OA21.02: ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism
  Alona Zer, Israel
  Jennifer King, USA
- 11:30 - OA21.04: Discussant:
  Navneet Singh, India
- 11:45 - OA21.05: Wet M1a Non-Small Cell Lung Cancer: Is It Possible to Predict Recurrence of Pleural Effusion?
  Riad Younes, Brazil
- 11:55 - OA21.06: Turning Best Supportive Care into Active Care. A Service Development for Patients with Advanced Lung Cancer in NHS Fife, Scotland
  Joanna Bowden, UK
- 12:05 - OA21.07: Discussant:
  Eva Masel, Austria
- 12:20 - Q & A

Room: Lehar 3-4
Chair: David Carbone, USA

- 12:45 - Welcome and Opening Remarks
  David Carbone, USA
- 12:50 - Immunotherapy Experience in Lung Cancer
  Naiyer Rizvi, USA
- 13:05 - The Value of Biomarkers in Lung Cancer
  Keith Kerr, UK
- 13:20 - Patient Management
  Thomas Newsom-Davis, UK
- 13:35 - Lung Cancer Landscape: Future Directions
  David Carbone, USA
- 13:50 - Panel Discussion
- 14:15 - Closing Remarks
  David Carbone, USA

14:20 - 15:50: Concurrent Abstract Sessions

Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
Room: Strauss 3
Chairs: Harvey Pass, USA & Nico van Zandwijk, Australia

- 14:20 - OA22.01: STELLAR - Interim Results of a Phase 2 Trial of TTFields with Chemotherapy for First Line Treatment of Malignant Mesothelioma
14:00 - 15:00: Oral Session (OA22): Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial
   Federica Grosso, Italy

14:30 - 15:00: Oral Session (OA22): HMGB1, a Target for Mesothelioma Therapy and a Biomarker to Detect Asbestos Exposure and to Identify Mesothelioma Patients
   Haining Yang, USA

14:30 - 15:00: Oral Session (OA22): Discussant: Christian Diego Rolfo, Belgium

15:00 - 15:30: Oral Session (OA22): Breath Analysis by Gas Chromatography-Mass Spectrometry Can Be Used to Screen for Pleural Mesothelioma
   Kevin Lamote, Belgium

15:30 - 16:00: Oral Session (OA22): Refinement of the Prognostic miR-Score for Use in Diagnostic Specimens from Chemo-Naïve Malignant Pleural Mesothelioma Patients
   Michaela Kirschner, Switzerland

15:30 - 16:00: Oral Session (OA22): Discussant: Viktoria Laszlo, Austria

14:20 - 15:00: Oral Session (OA23): EGFR Targeted Therapies in Advanced NSCLC

   Track: Advanced NSCLC
   Room: Stolz 2
   Chairs: Odd Terje Brustugun, Norway & Shun Lu, China

   Gilberto Lopes, Brazil

14:30 - 15:00: Oral Session (OA23): Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR-Expressing Tumors in SQUIRE, a Phase 3 Study
   Tudor Ciuleanu, Romania

14:40 - 15:00: Oral Session (OA23): Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial
   Glenwood Goss, Canada

14:50 - 15:00: Oral Session (OA23): Discussant: Martin Sebastian, Germany

15:00 - 15:20: Oral Session (OA23): First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7
   Keunchil Park, South Korea

   Kazushi Yoshida, Japan

   Fred R. Hirsch, USA

15:50 - 16:00: Oral Session (OA23): Discussant: Melissa Johnson, USA
Room: Stolz 1  
**Chairs:** Karin Dieckmann, Austria & Stefan Rieken, Germany

- **14:20 - OA24.01:** Radiotherapy Quality Assurance of Concurrent Chemoradiotherapy in PROCLAIM Phase III Trial  
  Anthony Brade, Canada
- **14:30 - OA24.02:** Locally Advanced Non-Small Cell Lung Cancer: RadioTherapy with Adaptive Strategy (LARTIA Trial)  
  Sara Ramella, Italy
- **14:40 - OA24.03:** Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose-Escalation Trials Delivering 70-90 Gy  
  Kyle Wang, USA
- **14:50 - OA24.04:** Discussant:  
  Fiona McDonald, UK
- **15:05 - OA24.05:** The Nordic HILUS-Trial - First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors  
  Karin Lindberg, Sweden
- **15:15 - OA24.06:** Histologic Subtype of Early-Stage Lung Adenocarcinoma is a Predictor of Failure Patterns after Stereotactic Body Radiation Therapy  
  Abraham Wu, USA
- **15:25 - OA24.07:** The Impact of Population Heterogeneity on the Efficacy of SBRT to the Lung  
  Mohamed Abazeed, USA
- **15:35 - OA24.08:** Discussant:  
  Feng-Ming (Spring) Kong, USA

**14:20 - 15:50:** Mini Oral Session (MA15): Immunotherapy Prediction  
Track: Chemotherapy/Targeted Therapy/Immunotherapy  
Room: Schubert 1  
**Chairs:** Maya Gottfried, Israel & Oscar Arrieta, Mexico

- **14:20 - MA15.01:** Immunogram for Cancer-Immunity Cycle towards Personalized Immunotherapy of Lung Cancer  
  Takahiro Karasaki, Japan
- **14:26 - MA15.02:** Non-Synonymous Mutation Burden in Lung Carcinoma is Associated with Durable Clinical Response to Immune Checkpoint Blockade  
  Navin Mahadevan, USA
- **14:32 - MA15.03:** The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC  
  Weijing Cai, China
- **14:38 - MA15.04:** Discussant:  
  Jürgen Fischer, Germany
- **14:50 - MA15.05:** PD-L1 Immunohistochemistry as Biomarker in Non-Small Cell Lung Cancer (NSCLC)  
  Dagmar Krenbek, Austria
- **14:56 - MA15.06:** Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)  
  Kurt Schalper, USA
- **15:02 - MA15.07:** Molecular Determinants of Lack of Tumor Immune Infiltration in NSCLC  
  Thomas Hensing, USA
- **15:08 - MA15.08:** Discussant:
Izidor Kern, Slovenia

- **15:20 - MA15.09: Response to the Treatment Immediately before Nivolumab Monotherapy May Predict Clinical Response to Nivolumab**
  Haruki Kobayashi, Japan

- **15:26 - MA15.10: Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma**
  Zhong-Yi Dong, China

- **15:32 - MA15.11: Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer**
  Kenichi Suda, USA

- **15:38 - MA15.12: Discussant:**
  Martin Früh, Switzerland

Track: Chemotherapy/Targeted Therapy/Immunotherapy
Room: Strauss 2
**Chairs:** Gunta Purkalne, Latvia & Joachim von Pawel, Germany

- **14:20 - MA16.01: Targeted Gene Therapy for Tobacco Carcinogen-Induced Lung Cancer**
  Nomundelger Gankhuyag, South Korea

- **14:26 - MA16.02: Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas**
  Katerina Politi, USA

- **14:32 - MA16.03: Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers**
  Oliver Gautschi, Switzerland

- **14:38 - MA16.04: Discussant:**
  Myung-Ju Ahn, South Korea

- **14:50 - MA16.05: For EGFR Mutant Non-Small Cell Lung Cancer, Treatment Sequence Matters?** - Ho Jung An, South Korea

- **14:56 - MA16.06: Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation**
  Yi Long Wu, China

- **15:02 - MA16.07: Drug Repurposing to Overcome De Novo Resistance of Non-Traditional EGFR Mutations**
  Jacqulyne Robichaux, USA

- **15:08 - MA16.08: Discussant:**
  Thanyanan Reungwetwattana, Thailand

- **15:20 - MA16.09: Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer**
  Alex Drilon, USA

- **15:26 - MA16.10: Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates**
  Vassiliki Papadimitrakopoulou, USA

- **15:33 - MA16.11: CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials**
  Glenwood Goss, Canada

- **15:38 - MA16.12: Discussant:**
  Edgardo Santos, USA

14:20 - 15:50: Mini Oral Session (MA17): Genetic Drivers
Track: Biology/Pathology
Room: Lehar 1-2
Chairs: Miyako Satouchi, Japan & George Simon, USA

- 14:20 - MA17.01: Microarray Identification of Genetic Drivers of Brain Metastasis in Lung Adenocarcinoma
  Gavitt Woodard, USA
- 14:26 - MA17.02: Genome-Wide Copy Number and Mutational Analysis in Longitudinal Biopsies of Matched Primary and Metastatic Pulmonary Adenocarcinomas
  Thomas Lorber, Switzerland
- 14:32 - MA17.03: Identifying Genomic Alteration and Inter-Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and ctDNA
  Kezhong Chen, China
- 14:38 - MA17.04: Discussant:
  József Timár, Hungary
- 14:50 - MA17.05: Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas
  Hao-ran Zhai, China
- 14:56 - MA17.06: Landscape of Somatic Mutations Involving Lung Cancer Associated Genes in Non-Small Cell Lung Cancer (NSCLC) Patient-Derived Xenografts
  Vibha Raghavan, Canada
- 15:02 - MA17.07: Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
  Maximilian Diehn, USA
- 15:08 - MA17.08: Discussant:
  Leonhard Müllauer, Austria
- 15:20 - MA17.09: Premature Fibroblast Senescence in Large Cell Carcinoma Provides Enhanced Growth and Invasive Advantages to Cancer Cells in Culture and in vivo
  Marta Gabasa, Spain
- 15:26 - MA17.10: YES1 Kinase is a New Therapeutic Target in Non-small Cell Lung Cancer
  Luis Montuenga, Spain
- 15:32 - MA17.11: Knockdown of Akt2 Suppresses Tumorigenesis and Raf1 Overexpression Offsets This Effect in Non-Small Cell Lung Cancer
  Shuang Zhao, China
- 15:38 - MA17.12: Discussant:
  Sanja Dacic, USA

14:30 - 15:45: Educational Session (ED14): Small Cell Lung Cancer
Track: SCLC/Neuroendocrine Tumors
Room: Hall C2
Chairs: Jens Benn Sørensen, Denmark & Sabine Zöchbauer-Müller, Austria

- 14:30 - Chemotherapy of Small Cell Lung Cancer
  Primo Lara, USA
- 14:45 - Thoracic Radiotherapy of SCLC
  Berend Slotman, The Netherlands
- 15:00 - Update on Prophylactic Cranial Irradiation in SCLC
  Takashi Seto, Japan
- 15:15 - Is there a Role for Surgery in SCLC?
  Georgios Stamatis, Germany
- 15:30 - Immunotherapy of Small Cell Lung Cancer
  Nevin Murray, Canada
14:30 - 15:45: Educational Session (ED15): Thymic Malignancies: Update on Treatment
Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
Room: Hall C1
Chairs: Heather Wakelee, USA & Paul Van Schil, Belgium

- 14:30 - Biology of Thymic Epithelial Tumors
  Giuseppe Giaccone, USA
- 14:50 - Chemotherapy and Targeted Therapies of Thymic Malignancies
  Nicolas Girard, France
- 15:10 - Surgery of Thymic Malignancies
  Meinoshin Okumura, Japan
- 15:30 - Radiation of Thymic Malignancies
  Andreas Rimner, USA

14:30 - 15:45: Science Session (SC30): Novel Approaches and Regulation in Surgical Education
Track: Surgery
Room: Hall C8
Chairs: Dominique Grunenwald, France & Young Tae Kim, South Korea

- 14:30 - Robotic Surgery: The Future in Thoracic Surgery?
  Housmanou Cheufou, Germany
- 14:50 - Animal Models for Training of Thoracic Surgeons
  Young Tae Kim, Korea
- 15:10 - E-Learning in Thoracic Oncology
  Jalal Assouad, France
- 15:30 - Impact of Working Time Directives on Thoracic Surgical Training: The North-American Experience
  Claude Deschamps, USA

Track: Scientific Co-Operation/Research Groups | Regional Aspects/Health Policy/Public Health
Room: Hall C7
Chairs: Michael Boyer, Australia & Pieter Postmus, UK

- 14:30 - The Role of Scientific Organizations
  Paul Bunn, Jr., USA
- 14:50 - The Role of Patient Advocacy Groups
  Bonnie Addario, USA
- 15:10 - The Role of Medical Journals
  David Collingridge, UK
- 15:30 - The Possibilities of Print & Social Media
  Wolfgang Wagner, Austria

14:30 - 15:45: Nurses Session (NU05): Survivorship
Track: Nurses
Room: Schubert 5
Chairs: Beth Ivimey, Australia & Maria Guerin, UK

- 14:30 - Use of Inspiratory Muscle Training in Managing Dyspnoea in Lung Cancer Patients
Andreas Charalambous, Cyprus

- 14:50 - Comprehensive Long-Term Care of Lung Cancer Patients: Development of a Novel Thoracic Survivorship Program
  James Huang, USA

- 15:10 - What can we Learn from Other Tumor Sites About Survivorship
  Natalie Doyle, UK

- 15:30 - Q&A

14:30 - 15:45: Young Investigator Session (YI02): Basics of Radio-Oncology
Track: Radiotherapy
Room: Strauss 1
Chairs: Corinne Faivre-Finn, UK & Rolf Lewensohn, Sweden

- 14:30 - PET-CT and MRI for Radiotherapy Planning of Lung Cancer
  Ursula Nestle, Germany

- 14:50 - Modern Treatment Techniques in Lung Cancer: The Advantages of Conformal Radiotherapy, IMRT and Proton Therapy
  Satoshi Ishikura, Japan

- 15:10 - Dose Limitations for Radiotherapy of Lung Cancer
  Antonio Juretic, Croatia

- 15:30 - Career Development in Radiation Oncology
  Laurie Gaspar, USA

14:30 - 15:45: Poster Session with Presenters Present (P3)
Room: Hall B (Poster Area)

- [Click here for the 17th IASLC WCLC Poster Program »]

16:00 - 18:00: Closing Plenary Session (PL05): A Life in Thoracic Oncology - Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer
Room: Hall C1
Chairs: Paul Bunn, Jr., USA & Tony Mok, Hong Kong

- 16:00 - PL05.01: Pathology
  Adi Gazdar, USA

- 16:15 - PL05.02: Surgery
  Peter Goldstraw, UK

- 16:30 - PL05.03: Radio-Oncology
  David Ball, Australia

- 16:45 - PL05.04: Translational Lung Cancer Research
  Nagahiro Saijo, Japan

- 17:00 - PL05.05: Chemotherapy
  Thierry Le Chevalier, France

- 17:15 - PL05.06: Targeted Therapy
  Frances Shepherd, Canada

- 17:30 - PL05.07: A Wise Man’s Conclusion
  Lawrence Einhorn, USA

- 17:45 - PL05.08: Welcome to Yokohama for WCLC 2017
  Hisao Asamura, Japan

- 17:55 - PL05.09: Farewell
  Robert Pirker, Austria
19:00 - 22:00: WCLC 2016 Together Against Lung Cancer (Ticketed Event: €99,00)
The Hofburg